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01 NEUROFERRITINOPATHY
Chinnery PF, Curtis AR, Fey C, Jackson MJ, Bates D, Morris CM, Bindoff LA,
Coulthard A, Ince PG, Curtis A, Burn J The University of Newcastle upon
Tyne, UK
We have identified an adenine insertion at position 460–461 in the ferri-
tin light polypeptide gene (FTL) in affected members of a large Cumbrian
family with a late-onset movement disorder. The clinical features of this dis-
ease are highly variable. Some individuals presented with a focal dystonia
in childhood which rapidly became generalised; others developed chorea
in adult life; and others were diagnosed as having a late onset
akinetic-rigid syndrome similar to idiopathic Parkinson’s disease. Brain
imaging was strikingly abnormal in some cases with cystic degeneration of
the caudate and lentiform nucleii. Postmortem examination revealed a
widespread abnormality of iron metabolism, particularly affecting the glo-
bus pallidus, which contained spherical inclusions of iron and ferritin. Fol-
lowing the identification of the first family, the same mutation has been
identified in other patients throughout Britain. In addition to possible links
to the United States, one member of the founder family was Fletcher Chris-
tian, who achieved fame as the leader of the mutiny on the Bounty. This
raises the possibility that other cases of this disease may live in the South
Pacific region. This family provides a direct link between a disorder of
brain iron metabolism and a neurodegenerative movement disorder, and
raises the possibility of treating the disease by modifying brain iron stores.
02 THE GENETIC BASIS AND PHENOTYPIC VARIABILITY IN
EARLY ONSET PARKINSONISM
Khan N, Valente EM, Brooks DJ, Piccini P, Bhatia KP, Quinn NP, Wood
NW Institute of Neurology, London, UK
Introduction: Three loci have been mapped in autosomal recessive
juvenile parkinsonsim: PARK2 (parkin) on chromosme 6 and PARK6
and PARK7 both on chromsome 1. Mutations in PARK2, parkin,
are a common cause of young onset parkinsonism. PARK6 has been
linked to early onset parkinsonism to chromosome 1 in a Italian
kindred. A further eight unrelated families from different parts of
Europe have been shown to be linked to the same region suggesting
that it may also account for a share of autosomal recessive parkinson-
ism.
Here we summarise the genetics, clinical phenotype and 18F-dopa
PET studies in both parkin disease and PARK6-linked parkinsonsim.
Methods: PARK2: we have identifed 24 patients with parkin muta-
tions using sequencing and semi-quantitative PCR techniques. We
have carried out a detailed clinical evaluation using a standardised
clinical proforma. A cohort of these patients have undergone 18F-dopa
PET.
PARK6: a clinical evaluation of the Marsala family in which parkin-
sonism was first linked to chromosome 1 and other unrelated families
linked to PARK6 was performed. Four patients with PARK6-linked par-
kinsonsim and three carriers of a single mutant PARK6 underwent 18F-
dopa PET.
Results: Parkin disease and PARK6-linked parkinsonsim are
distinct genetic entities with an overlap in the clinical phenotype. We
report three new phenotypes at presentation in parkin disease:
exercise-induced dystonia, focal dystonia and autonomic neuropathy
with peripheral neuropathy. Both PARK2 and PARK6-linked parkinson-
ism have nigrostraiatal F-dopa uptake in both caudate and putamen
which is unlike that of IPD.
Conclusion: PARK6-linked parkinsonsim has a phenotype that
shares features of both IPD and parkin disease 18F-dopa PET however
suggests that it is an atypical form of parkinsonism. Preliminary work
suggests that PARK6 contributes to a share of young onset parkinson-
ism. Parkinsonism due to mutation in PARK2 is an important cause of
young onset parkinsonism that should be considered in the diagnostic
work up.
ABN MEDAL AWARD 2002
Dr Pauline Monro
Pauline Monro was an outstanding medical student, gaining first class honours in her BSc at University College London, and
then distinction in both medicine and pathology when she qualified from University College Hospital in 1958. She was also
a competitive swimmer, winning a gold medal in the World University Games at Dortmund in 1953.
Like many others, she was inspired to go into neurology by JZ Young whom she had heard—while still at school—give the
Reith lectures. Despite the challenges at a time when there was less than a handful of female consultant neurologists in the
United Kingdom, and an almost fatal illness late in her training, she was appointed a consultant to Atkinson Morley’s Hospi-
tal, London, in 1970—the first woman to be appointed to the consultant staff of the St George’s Hospitals.
At AMH she threw her energies into creating one of the best neurosciences centres in the United Kingdom, encouraging
multidisciplinary team meetings before they were fashionable, and developing an integrated neurology course for the medical
students. Such was her charisma, that I can actually remember the teaching round when she explained to us the difference
between upper and lower motor neuron lesions when I was a St George’s medical student in 1967. She retired from the NHS
in 1993 and later became the first woman to be President of the Section of Neurosciences at the Royal Society of
Medicine.
As a result of going on the ABN visit to Leningrad in 1988, Pauline became passionately involved with helping the neuro-
logical services in what had by then become St Petersburg, as well as in Russia generally. She became so fluent in Russian
from a standing start that she can now lecture easily in the language, bought a flat in St Petersburg, and befriended young
Russian neuroscientists. All this culminated in the most deserved award of an MBE in 2000. This is really her life work, more
than being an NHS consultant, however successful—as she told me recently “driving across Europe to Russia in an ambulance
with Zimmer frames is much more interesting than being an NHS neurologist”.
Despite the loss of Michael, her beloved husband and partner, in 2000, Pauline continues her work in Russia with as much
energy as ever. I can’t believe she will ever stop shuttling backwards and forwards to Russia with yet another small band of
British physiotherapists or nurses going one way and their Russian counterparts coming the other. When Pauline first went to
Russia, neurological care there had been isolated from the West for 70 years. Now, encouraged and helped by Pauline, the
first multidisciplinary stroke team in Pavlov’s Medical University Hospital is accepted by the local Committee of Health as a
model centre, one of many examples of good practice which are springing up across the city. In St Petersburg she is known
to everyone as Paulina, and so it is with great pleasure that I invite you—Paulina—to give your lecture entitled “Russian and
British neurology: contacts and contrasts”.
CHARLES WARLOW
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03 RE-EMERGENCE OF ENCEPHALITIS LETHARGICA: NEW
EVIDENCE OF AN AUTOIMMUNE CNS DISEASE
Dale RC, Church AJ, Surtees RAH, Lees AJ, Neville BGR, Giovanni G Insti-
tute of Neurology; Institute of Child Health, London, UK
Background: Encephalitis lethargica (EL) is an acute encephalitic ill-
ness with somnolent-ophthalmoplegic, hyperkinetic and Parkinsonian
phenotypes. Pathology reveals inflammatory disease of the basal gan-
glia and midbrain. The presence of CSF oligoclonal bands, and
improvement after steroid treatment have suggested that EL may be
immune-mediated.
Methods: We report on five children and one adult with EL. The
serum and CSF was examined for the presence of anti-neuronal anti-
bodies using western immunoblotting and immunofluorescence. 200
children and adult controls were used for comparison.
Results: All six patients had evidence of autoantibodies reactive
against basal ganglia neurones in both serum and CSF. The basal
ganglia antigens involved in antibody reactivity were of molecular
weight 40, 45 and 60 kDa. Positive binding was seen in 3% of pae-
diatric and adult controls (n=200). Three patients with the
parkinsonian phenotype had a similar binding pattern to midbrain
(substantia nigra) neurons. There was no binding to neural antigens
from other brain regions. Four patients had evidence of a preceding
streptococcal infection.
Conclusion: We propose that EL is a postinfectious autoimmune
CNS disorder with auto-antibody targeting of the basal ganglia and
substantia nigra neurons. EL is still endemic in the population with the
potential to reappear in epidemic forms.
04 NATURAL HISTORY OF MULTIPLE SCLEROSIS:
IMPLICATIONS FOR INTERPRETATION OF RELAPSE
SUPPRESSION
Ebers GC University of Oxford, UK
Background: It is still widely believed that the progression of disabil-
ity in multiple sclerosis results from accumulative effect of focal exacer-
bations. Although this is most clearly true for patients with the Devic’s
phenotype, it has not been formally shown in the great majority of MS
patients who begin with exacerbations and subsequently develop sec-
ondary progressive disease (SPMS). It is clear that the number of
exacerbations in the first 2 years has an important association with
long term outcome. We examined here the association between
relapses and the onset of progression, and in addition time to long
term disability using DSS 6, 8, and 10.
Methods: The study was population based and derived from a
cohort of 1042 patients from the London, Ontario MS clinic. The fol-
low up entails some 25000 patient years of observation. The patients
were seen approximately yearly over their period of observation. The
DSS scale (Kurtske) was used for measurement of disability.
Results: Although an association was found between early
exacerbations and long term disability, this relationship did not
appear to be causal. The total number of relapses through the course
of the disease bore no relationship to long term outcome. The accumu-
lation of disability appears to be secondary to a relapse-independent
process.
Discussion: These findings imply that suppression of relapses will
have little effect on long term disability and are consistent with an
expectation of no effect. Modelling of outcome based on clinical fea-
tures has identified characteristics which correlate with disability well
in excess of R= 0.9. These findings far surpass correlations with any
surrogate markers. Since long term disability is primarily determined
by the progressive phase of the illness, outcome measures need to be
reconsidered and we propose some which seem to have more ration-
ale than those presently in use.
05 THE PREDICTIVE VALUE OF BRAIN LESION LOAD IN
DETERMINING BRAIN ATROPHY IN MULTIPLE
SCLEROSIS: 14 YEAR FOLLOW UP DATA FOLLOWING
FIRST PRESENTATION WITH A CLINICALLY ISOLATED
SYNDROME
Chard DT, Brex PA, Ciccarelli O, Griffin CMB, Dalton C, Thompson AJ,
Miller DH Institute of Neurology, London, UK
Background: Studies suggest that brain lesion load and atrophy may
be related in multiple sclerosis (MS), but the time course of this
relationship is unclear. This study investigates the relationship between
brain atrophy and lesion load in subjects followed up for 14 years
after a clinically isolated syndrome (CIS).
Methods: Twenty nine control subjects and 31 subjects followed
up after developing a CIS were studied. At 14 year follow up, four
subjects remained diagnosed with a CIS, four had clinically probable
and 23 had clinically definite MS. In patients, MRI determined T2
lesion load was assessed at baseline, 5, 10, and 14 years, along with
brain volume as a fraction of total intracranial volume (brain
parenchymal fraction [BPF]) at 14 years. Differences in MS BPF com-
pared to controls were estimated.
Results: The Spearman correlation of change in T2 lesion load
from baseline to 5 years with 14 year BPF reduction (rs=20.619,
p<0.001) was stronger than for subsequent change in lesion load.
Discussion: Change in lesion load in the first 5 years after clinical
onset is a stronger predictor of subsequent atrophy than later changes.
This suggests that early inflammation influences later neurodegenera-
tion in MS.
06 β-INTERFERON TREATMENT DOES NOT IMMEDIATELY
SLOW THE PROGRESSION OF AXONAL INJURY IN
MULTIPLE SCLEROSIS
Parry A, Corkill R, Blamire A, Palace J, Narayanan S, Arnold D, Styles P,
Matthews PM John Radcliffe Hospital, Oxford, UK; Radcliffe Infirmary,
Oxford; McGill University; Montreal Neurological Hospital and Institute,
Quebec
Progression of disability in multiple sclerosis (MS) appears related to
axonal damage in white matter. Histopathological studies have linked
inflammatory activity directly to axonal injury and transection.
β-Interferon (BIFN) substantially reduces new inflammatory activity in
MS.
To test whether BIFN treatment can arrest the progression of axonal
injury in patients with MS, 11 patients with active relapsing remitting
MS were treated with BIFN and serial MRI and magnetic resonance
spectroscopic measurements of N-acetylaspartate (NAA)—a measure
of axonal injury—were performed before and during treatment.
As expected relapse rate reduced (p=0.007), measures of cerebral
oedema (white matter T2 relaxation time) improved (p=0.04) and
lesion volume stabilised. In contrast, white matter NAA/creatine con-
tinued to decline (p=0.02). Interestingly, the magnitude of the NAA/
creatine decrease was correlated with the frequency of relapses over
the two years prior to treatment (r=20.76, p=0.006).
Thus either both processes are occurring independently, or the con-
sequences of reduced inflammation on axonal injury are substantially
delayed. This important distinction requires further study.
07 VALIDATION OF THE MCDONALD CRITERIA IN
PATIENTS WITH CLINICALLY ISOLATED SYNDROMES
Dalton CM, Brex PA, Miszkiel KA, Plant GT, Hickman SJ, MacManus DG,
Thompson AJ, Miller DH. Institute of Neurology; Lysholm Department of
Neuroradiology; Moorfields Eye Hospital, London, UK
Background: Traditionally, multiple sclerosis (MS) has been diag-
nosed on the basis of clinical evidence of dissemination in time and
space. Recently the international panel on MS diagnosis published the
McDonald criteria which have integrated MRI and included patients
with clinically isolated syndromes (CIS).
Methods: Patients with CIS were imaged at baseline, 3 months, 1
year and 3 years to determine the frequency with which patients with
CIS fufilled the traditional Poser criteria for clinically definite MS and
the new McDonald criteria for MS. The reliability of the McDonald cri-
teria was assessed using CDMS as the gold standard.
Results: At 3 months 20/95 (21%) had MS using the McDonald
criteria whereas only 7/95 (7%) had developed CDMS. After 3 years
the corresponding figures were, 29/50 (58%) and 19/50 (38%).
Development of MS using the McDonald criteria at 3 months had high
specificity (93%), positive predictive value (85%), negative predictive
value (82%) and accuracy (83%) but lower sensitivity (65%) for CDMS
at 3 years.
Discussion: Specificity is more important than sensitivity when
diagnosing lifelong conditions such as MS. The specificity and positive
predictive value of the McDonald criteria at 3 months for CDMS at 3
years was high, therefore the new criteria are valid.
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08 ISOLATED ASYMMETRIC DOMINANTLY POSTURAL
TEMOR WITH OR WITHOUT RESTING TREMOR: A
VARIANT PRESENTATION OF LONG LATENCY
TREMULOUS PARKINSON’S DISEASE? A CLINICAL
FOLLOW UP
Pal S, Peng R, Brooks DJ, Rao CS, Ray Chaudhuri K Kings College Hospi-
tal, London, UK; First University Hospital, Chengdu, China; Hammersmith
Hospital, London
Background: Considerable diagnostic uncertainty exists in patients
presenting with isolated asymmetric postural tremor (PT), with or with-
out resting tremor (RT) in the absence of significant bradykinesia, or
rigidity. Whether such patients demonstrate an “atypical” pattern of
essential tremor (ET) or ultimately progress to develop Parkinson’s dis-
ease (PD) and thus are misdiagnosed as ET, is unclear.
Methods: Twelve patients (seven male, mean age 55.7 (range
45–68)) initially presenting with isolated asymmetric PT±RT and erro-
neously diagnosed as ET by neurlogists/geriatricians at presentation
but developing signs of PD during clinical follow up or “re-referral”
were identified from our clinical database.
Results: Mean duration of PT prior to diagnosis of PD was 12.8
years ranging up to 40 years (range 5–40). Six patients had a family
history of ET and three a family history of PD. Nine cases
demonstrated both postural and resting tremor, the remainder having
asymmetric PT without bradykinesia at presentation. Alcohol or
propanolol sensitivity was recorded in four patients with PT and RT.
Dopaminergic therapy was of symptomatic benefit in all treated cases
(n=10).
Discussion: Tremulous PD should be considered in prognostic
counselling of patients presenting with asymmetric isolated PT ± RT
even if other diagnostic criteria for PD are not satisfied.
09 ANTIPARKINSONIAN ACTIONS OF THE SELECTIVE
DOPAMINE D3 RECEPTOR ANTAGONIST S33084
Silverdale MA, Millan MJ, Newman-Tancredi A, Crossman AR, Brotchie JM
Manchester Movement Disorders Laboratory, UK
The significance of dopamine D3 receptors in the control of movement
remains unclear. It has been suggested that D3 agonist properties
of widely used D2/D3 agonists such as ropinirole (hD3, Ki=56 nM
and hD2, Ki=154 nM) and pramipexole (hD3, Ki=9 nM and hD2,
Ki=182 nM) account for their control of Parkinson’s disease. The lack
of highly selective dopamine D3 receptor antagonists has hampered
study of their role. S33084 (hD3, Ki=0.4 nM and hD2, Ki=57 nM)
displays >100-fold selectivity for hD3 versus D2 receptors.
These drugs were administered to 1-Methyl-4-phenyl-1, 2, 3,
6-tetrahydropyridine (MPTP) lesioned marmosets previously
primed with levodopa to elicit dyskinesia. S33084 potentiated anti-
parkisonian actions of levodopa (p<0.05) and ropinirole
(p<0.01). There was no significant effect on dyskinesia. The action of
ropinirole was reduced by L741, 626 (p<0.05). Alone, S33084
exerted a modest but significant antiparkinsonian effect (p<0.05).
Employing selective D3 versus D2 receptor antagonists, we provide
evidence that stimulation of D3 receptors compromises motor function.
We conclude that clinically available D2/3 agonists exert anti-
parkinsonian actions via D2 rather than D3 receptors. Indeed,
stimulation of D3 receptors may be detrimental to antiparkinsonian
efficacy.
10 CLINICAL FEATURES OF THE GESTE ANTAGONISTE IN
CERVICAL DYSTONIA
Filipovic SR, Jahanshahi M, Viswanathan R, Heywood P, Bhatia KP, Rog-
ers D Institute of Neurology, London; Burden Neurological Institute and
Frenchay Hospital, Bristol, UK
A unique feature of dystonia is that patients are often able to reduce/
eliminate the abnormal posture by using certain manoeuvres that
involve tactile or proprioceptive stimulation. Although widely
recognised, these manoeuvres or “gestes antagonistes” (GA), have
not been systematically analysed. To assess this phenomenon in more
detail, we developed and administered a questionnaire to 100
successive patients with idiopathic cervical dystonia (CD) attending
two botulinum toxin clinics (London and Bristol). Almost 2/3 patients
(64%) reported a GA. There were no differences between patients
with and without a GA in terms of age, sex, duration of disease,
clinical presentation, and age at onset. Among those with a GA, 58%
discovered their GA within the year of CD onset, and in the majority
(91%) the GA was still effective. The GA target spots were mostly
located on the cheek (53%) and chin (43%), back of the neck (45%)
and head (35%). The index (60%) and middle (48%) fingers and the
palm (40%) were the most used for eliciting the GA. Touching the GA
target spot with an object was effective for 27%, while other people
were able to elicit the effect by touching the GA target in 27% of
patients. The majority (84%) reported that the GA improves their CD
by at least 50%, while almost one third (30%) felt that the GA
improves their CD “greatly” (ie >75%) or “completely”. The GA
effect was judged to be slightly better for improving head/neck/
shoulder position than for changing neck and shoulder movements
and pain.
The almost ubiquitous presence and remarkable efficacy of the GA
in CD warrants further investigation of its physiology which may pro-
vide clues for understanding the neurobiology of dystonia and open
new avenues for its treatment.
11 IS DYSTONIA A DISORDER OF MUSCLE?
Frima N, Grunewald RA University of Sheffield, UK
Background: The vibration induced illusion of movement (VIIM) is
subserved by muscle spindle Ia afferents, and is subnormal in dystonic
subjects. We examined the effect of muscle fatigue on VIIM and its
perception in asymptomatic first degree relatives.
Methods: Nineteen patients with torticollis (mean age 55.37)
were compared to 18 healthy control subjects (mean age 58.9). Nine
parents, 20 siblings and 11 children were compared to 13 dystonic
probands (mean age 55) and healthy control subjects. 80 Hz
vibration was applied to the biceps brachii tendon with the arm fixed
in a splint. Relaxation of the arm was verified by surface EMG. Blind-
folded subjects were asked to copy the perceived movement of the
vibrated arm with their other arm. Extension of the tracking arm was
measured over 45 seconds. The task was repeated following fatigue
of the vibrated arm.
Results: Perception of VIIM was less in dystonic patients
(19.1°+/21.86; mean change of angle ±2SE) than controls(
28.81°+/21.74; mean ±2SE), (p<0.01, unpaired t test), but
increased in dystonic subjects when the vibrated arm was fatigued
(24.68°±22.5; mean+/2SE, p=0.01, paired t test compared with
prefatigued values). (2/13) 85% of index patients, (19/37) 51% of
first degree relatives, and (5/18) 28% of healthy controls had abnor-
mal VIIM.
Discussion: These results imply that abnormal muscle spindle func-
tion in dystonia is genetically determined, and that muscle fatigue has
a role in the genesis of dystonia in predisposed individuals.
12 ANTIEPILEPTIC DRUGS IN PREGNANCY: UPDATE OF THE
UK EPILEPSY AND PREGNANCY REGISTER
Craig J, Russell A, Morrison P, Guthrie E, Parsons L, Waddell R, Morrow J
Royal Group of Hospitals, Belfast, Northern Ireland, UK
Objective: To determine the relative risks for major congenital
malformations (MCM) of in utero exposure to antiepileptic drugs
(AEDs).
Design—Prospective, observational, registration and follow up
study.
Subjects: —Women with epilepsy who become pregnant,
whether or not they are taking an AED, either singly or in combination,
and who are referred before outcome of the pregnancy is known.
Outcome measure: MCM for each AED regime for exposed
pregnancies.
Results: Full outcome data are available on 1714 pregnancies
from 1996 through November 2001, with 595 outcomes awaited.
Monotherapy exposures account for 72% (MCM rate 4.4% [95% CI
3.4–5.8%]), polytherapy exposures for 23% (MCM rate 5.3% [95%
CI 3.4–8.2%]), and no AED exposures for 5% (MCM rate 1.1% [95%
CI 0.1–6.2%]) of cases. Although the MCM rate for carbamazepine
(3.1% [95% CI 1.9–5.1%] and lamotrigine (2.8% [95% CI 1.3–6.0%)
are less than that recorded for sodium valproate (7.3% [95% CI 5.0–
10.4%]) the differences are not statistically significant.
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Conclusions: The UK Epilepsy and Pregnancy Register is proving
an effective method of collecting outcome data on large numbers of
pregnancies occurring in women with epilepsy. The results suggest
that there are possible differences in MCM rate between AEDs, but
further cases are required to establish the degree of these differences
and the influence of other confounding variables.
13 NURSE LED EPILEPSY CLINICS: A TELEMEDICINE
APPROACH
Bingham E, Patterson V. Royal Victoria Hospital, Belfast, Northern Ireland,
UK
Patients with epilepsy consistently express a desire to see nurse
specialists as well as a neurologist. We have developed nurse led epi-
lepsy clinics at two rural hospitals, supported by telephone and
videolink to a distant neurologist and here report on the feasibility,
satisfaction, and cost of this method. An experienced epilepsy nurse
(EB) assessed review patients with epilepsy at the clinics of a consult-
ant neurologist (VP) at district general hospitals 75 and 85 miles
respectively from the Neurological Centre. If further advice was
needed, she telephoned the distant neurologist. If necessary the
neurologist arranged a real time videolink with the nurse and patient.
Satisfaction was assessed by a simple questionnaire using a three
point Likert scale. The time spent by the patient with the nurse and the
neurologist was documented and costed. One hundred and fifty five
patients were seen over an 11 month period. Fifty five (35%) were
managed solely by the nurse, 55 (35%) needed a telephone call, and
45 (29 %) required a video link. Seventy six per cent of all patients
preferred the telemedicine. Neurologist time was reduced by 80%.
Overall cost increased from £12.87 to £17.59 per patient. Nurse led
epilepsy clinics supported by a distant consultant neurologist using
telemedicine, are feasible, more acceptable, but more expensive than
conventional care.
14 QUANTITATIVE VALIDATION OF MR INTENSITY
ABNORMALITIES IN VARIANT CJD
Colchester ACF, Hojjat SA, Will RG, Collie DA University of Kent, UK, and
Western General Hospital, Edinburgh, Scotland, UK
High signal in the posterior thalamus on MRI scanning has emerged as
an important diagnostic sign in variant Creutzfeldt-Jakob disease. We
carried out quantitative analysis of 39 dual echo (PD and T2) MRI
scans from a variety of scanners. 11 were from proven vCJD patients
and 28 were from controls (12 sCJD and 16 non-CJD dementia
cases). Absolute intensities vary greatly between scans, and the
usefulness of different strategies for estimating relative intensities was
examined.
Calculating the posterior thalamus to putamen intensity ratio on T2
scans, and using a threshold of 1.0, was 100% sensitive for vCJD
against controls but the specificity was only 20%; while using the cau-
date instead of the putamen as a reference structure gave a good bal-
ance of sensitivity (82%) and specificity (93%). On PD scans the
putamen was the better reference structure, giving 91% and 86%
respectively. The best diagnostic discrimination overall was achieved
with the posterior thalamus to frontal white matter ratio on T2 scans by
using a threshold of 1.51, giving 100% sensitivity and 89%
specificity.
These quantitative results, on scans acquired at many different cen-
tres, have provided objective validation of published visual
judgements and have confirmed that use of non-unity thresholds can
improve discrimination further.
15 MAPPING THE EVOLUTION OF REGIONAL ATROPHY OF
REGIONAL ATROPHY IN ALZHEIMER’S DISEASE USING
FLUID REGISTERED MRI
Schott JM, Scahill RI, Stevens JM, Rossor MN, Fox NC Dementia Research
Group, National Hospital for Neurology and Neurosurgery, London, UK
Objective: To assess altering patterns of significant regional atrophy
during the progression of Alzheimer’s disease (AD).
Methods: Patients with presymptomatic AD (n=4), mild AD (n=10)
and moderate AD (n=12) were compared with age and sex matched
controls. All subjects had two serial MRI scans. Non-linear (fluid)
registration was performed on the scan pairs, and statistical paramet-
ric mapping was used to demonstrate regions showing consistent sig-
nificant (p<0.001) expansion or contraction between each group and
controls.
Results: We demonstrated increasing global atrophy with
advancing disease. In presymptomatic individuals rates of atrophy
were significantly increased in both hippocampi and the precuneus. In
mildly and moderately affected patients the most significantly
increased rates of atrophy were seen in the inferior and lateral tempo-
ral lobes, precuneus, and cingulate.
Conclusions: We demonstrated changes in the localisation of the
most active areas of volume loss as AD progresses. Whilst measures
of hippocampal change may be most useful at the earliest stages of
the disease, the precuneus and posterior cingulate, which show
significant, consistent and increasing rates of atrophy with increasing
severity may prove to be useful indices of progression throughout the
course of the disease.
16 EARLY EXPERIENCE WITH MITOXANTRONE IN
AGGRESSIVE RELAPSING-REMITTING MULTIPLE
SCLEROSIS
Ezhil V, Boggild M The Walton Centre for Neurology and Neurosurgery,
Liverpool, UK
Background: Data from three randomised controlled trials supports
the use of mitoxantrone, a cytotoxic agent, in active relapsing and
secondary progressive multiple sclerosis (MS). The drug has recently
been licenced in the United States for “worsening” relapsing remitting
and secondary progressive MS. Dosage is limited by cumulative car-
diotoxicity to a maximum of 120 mg/m2. We report experience from
one centre on the use of this agent in patients with aggressive
relapsing-remitting MS (RRMS).
Patients: 18 Patients have been treated (11 female), mean age
34.6 (range 20–47), mean disease duration 4.1 years. All patients
had experienced two or more disabling relapses with incomplete
recovery in the preceding year. Mean Expanded Disability Status
Scale (EDSS) prior to treatment was 6.1. All patients underwent regu-
lar ECG and Echocardiography for left ventricular ejection fraction.
Results: There were no major adverse events, only one patient
elected to discontinue treatment (at 18 months, disability stable).
Mean duration of treatment was 17 months. In the 2 years prior to
treatment the cohort had 60 steroid treated relapses (ARR 1.66), on
treatment there were six relapses (ARR 0.35). At most recent follow up,
or withdrawal of treatment, EDSS was stable (+/20.5 points) in 11
and improved (=1 point) in seven (mean EDSS 5.0).
Conclusions: Although we would acknowledge that the data we
report is uncontrolled; in patients with very active RRMS mitoxantrone
seems to be highly effective in suppressing relapse activity. The drug
is well tolerated over periods of up to 24 months. Further studies
examining the use of Mitoxantrone as an ‘induction’ agent in patients
with aggressive disease, prior to the use of standard disease modify-
ing drugs, should be considered.
17 INTRATHECAL IMMUNE RESPONSE AGAINST AXONAL
CYTOSKELETAL COMPONENTS IN PATIENTS WITH
MULTIPLE SCLEROSIS: A PROGNOSTIC STUDY
Seidi OA, Semera YK, Gregson NA, Sharief MK GKT School of Medicine,
London, UK
Background: We have recently reported a significant correlation
between clinical disability and intrathecal release of antibodies
against axonal cytoskeleton in patients with primary and secondary-
progressive MS.
Objectives: To determine the prognostic value of intrathecal
antibodies to axonal proteins for future development of disability in
MS patients.
Methods: In a prospective study, we measured intrathecal levels of
antibodies against actin, tubulin and neurofilament light-subunit from
51 patients with relapsing-remitting, secondary, or primary progres-
sive MS. Patients were clinically monitored for 2 years after the lumbar
puncture (LP). We included 52 patients with other neurological disor-
ders and eight healthy subjects, as controls. We also measured anti-
bodies against myelin basic protein (MBP) as a control antigen.
Results: Intrathecal levels of antibodies against all axonal
proteins, but not anti-MBP, correlated with the EDSS score at the time
of LP. Moreover, MS patients with high intrathecal levels of antibodies
against axonal proteins accumulated more neurological disability at
the end of the two years period compared to patients with low levels.
In contrast, antibodies against MBP did not correlate with EDSS score
at the end of the study.
Conclusion: These findings suggest that the determination of
intrathecal antibodies against axonal proteins may be clinically useful
in MS patients.
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18 OLIGODENDROCYTES PROMOTE THE SURVIVAL OF
AXONS IN VITRO
Wilkins A, Chandran S, Layfield R, Compston DAS Cambridge Centre for
Brain Repair, Cambridge, UK
Background: Late onset axonopathy, occurring in the absence of
inflammation, is an increasingly recognised feature of multiple sclero-
sis. The pathophysiology of this process however remains unknown,
but loss of trophic support provided by oligodendrocytes, which are
depleted in chronically demyelinated plaques, is one potential cause.
We have therefore investigated oligodendrocyte influences on
neurons and specifically on axons.
Methods: Rat neurons were cultured in oligodendrocyte condi-
tioned medium (OCM) or non-conditioned medium (NCM). At
determined time points, the cultures were stained with antibodies
against axon specific proteins and axon length measured. Cell signal-
ing analyses were carried out by western blotting.
Results: Neurons conditioned in OCM showed approximately
50% increase in axon length per neuron compared to those cultured
in NCM. Furthermore inhibition of MAPkinase/Erk intracellular signal-
ling pathway, which was activated by OCM, reduced this effect sig-
nificantly.
Discussion: We have shown that soluble factors released by
oligodendrocytes increase the survival of axons in culture, which may
have important implications in determining the causes of axonopathy
in multiple sclerosis. The identification of neurotrophic factors
produced by oligodendrocytes may also lead to therapeutic strategies
to prevent irreversible axon loss in late stages of the disease.
19 A 5 YEAR LONGITUDINAL MRI STUDY OF VENTRICULAR
VOLUME IN PRIMARY PROGRESSIVE MULTIPLE
SCLEROSIS
Ingle GT, Stevenson VL, Leary SM, Miller DH, Thompson AJ Institute of
Neurology, London, UK
Background: Progressive atrophy resulting from axonal loss is one of
the proposed mechanisms underlying disability in Primary progressive
multiple sclerosis (PPMS). In this lengthy study of PPMS we measure
ventricular changes over 5 years.
Methods: 41 PPMS patients representing a wide range of ages
and disease duration attended for MRI and clinical examination at
baseline, 1, 2 and 5 years. 2D T1 weighted images were used to
measure ventricular volume at each time point using a semi-automated
iterative morphological technique.
Results: Over 5 years there was a significant increase in ventricu-
lar volume (p<0.0001) and the mean rate of change, by linear
regression, was 1.14 ml per year. Despite considerable variation in
rate between patients (from 0.6 to 6.6 ml per year), change over time
appeared relatively constant for a given patient. There was no corre-
lation between rate of ventricular enlargement and change in physical
disability but an association was found with deteriorating cognitive
function (r=0.34 p=0.034).
Discussion: In conclusion, ventricular enlargement is a sensitive
measure of change in PPMS and demonstrates clinical validity with
respect to cognitive function. It may also identify PPMS patients with
early high ventricular enlargement rates who would benefit from
therapeutic intervention.
20 TEN YEAR SURVIVAL DATA FROM THE SCOTTISH MND
REGISTER
Forbes RB, Colville S, Parratt J, Chancellor A, Davenport R, Swingler RJ The
Scottish MND Register, Ninewells Hospital, Dundee, UK
Aim: to describe survival from MND using a 10 year population-
based disease register.
Methods: survival analysis of Scottish adults with MND diagnosed
between 1989 and 1998, using time-dependent cox regression.
Results: 1226 cases were registered, 54% were male and the
mean age at onset was 64.7 years. 1054 cases (86%) had been
assessed by a neurologist. The first 614 cases were classified using
the revised WFN criteria, and the El Escorial criteria have been used
subsequently. The overall mean and median survival from symptom
onset was 33.5 (SD 22.9) and 24.7 (IQR 15.6–40.8) months respec-
tively. There was no influence upon survival of sex or family history.
Shorter survival was associated with bulbar symptoms at onset
(HR=1.25 (95%CI 1.08–1.44)), older age at onset (HR=1.02 (95%CI
1.01–1.03)) or presence of both upper and lower motor neuron signs
at registration (HR=1.22 (95%CI 1.02–1.47)). Improved survival was
significantly associated with longer duration from symptom onset to
diagnosis (HR=0.38 (95%CI 0.33–0.42)), assessment by a neurolo-
gist (HR=0.58 (95%CI 0.42–0.79)) and treatment with Riluzole
(HR=0.24(95%CI 0.14–0.40)). Even allowing for different diagnostic
criteria, there was a decline in median survival of 3 months between
the first (1989–93) and second (1994–98) half of the study period.
Conclusions: survival from MND is explained by commonly iden-
tified clinical variables. There is a strong association between assess-
ment by a neurologist and increased survival. The unanticipated
decline in survival identified in the second half of the cohort remains
unexplained.
21 NEUROLOGICAL AND COGNITIVE DYSFUNCTION IN
“NEVER-ENCEPHALOPATHIC” PATIENTS AWAITING
LIVER TRANSPLANTATION
Lewis MB, Stroud A, Davies M, Howdle PD St James’s University Hospital,
Leeds, UK
Introduction: Patients with liver failure who are not clinically
encephalopathic can show evidence of neuropsychological impair-
ment. Inadequate treatment of previous hepatic encephalopathy is
often blamed. Repeated episodes of hepatic encephalopathy (HE) are
thought to underlie the acquired hepatocerebral degeneration
syndrome (AHCD).
Method: Patients listed for liver transplantation with no history of
hepatic encephalopathy were assessed using a battery of neuro-
psychological tests and a structured neurological examination. Twenty
five healthy volunteers were used as controls.
Results: Twenty patients were included. There were no significant
differences between baseline characteristics of patients and controls.
Highly significant global impairment of cognitive function was
detected, with memory and visuospatial problems being prominent.
No abnormalities were detected with the commonly used trail making
test. Twelve patients had an abnormal neurological examination
displaying many of the physical signs associated with AHCD.
Discussion: Cognitive and neurological dysfunction occurs in
patients with end stage liver failure in the absence of previous HE. The
impairment that occurs is severe, and affects many aspects of
cognitive function. This has implications for the preoperative counsel-
ling of these patients and for obtaining informed consent. Current
methods of monitoring cognitive impairment clinically, such as
trailmaking tests, may be inadequate.
22 ARE VERTEBROBASILAR TERRITORY TIAS AND MINOR
STROKES LOWER RISK THAN CAROTID TERRITORY
EVENTS?
Flossmann E, Rothwell PM Stroke Prevention Research Unit, Radcliffe
Infirmary, Oxford, UK
Vertebrobasilar (VB) TIAs and minor strokes are perceived to have a
better prognosis than carotid events, and are sometimes managed less
aggressively. However, this notion stems mainly from a few small stud-
ies in the 1960s and 70s, which did not report overall rates of vascu-
lar death, and it has never been systematically studied.
We reviewed all published studies of prognosis following a TIA or
minor stroke using MEDLINE and EMBASE, and by hand searching
reference lists and relevant journals. 820 abstracts were reviewed,
and 303 papers were read in detail. 43 studies reported outcomes by
territory of presenting event. Odds of recurrent events were calculated
within studies and combined by fixed effects meta-analysis.
Patients presenting with VB events had a lower risk of recurrent
stroke than those with carotid events (OR=0.7, 95%CI 0.6–0.8,
p<0.00001, 33 studies), but a higher risk of recurrent TIA (OR=1.9,
95%CI 1.5–2.4, p<0.00001,12 studies), and the same risk of death
(mainly vascular) (OR=1.0, 95%CI 0.8–1.2, p=0.95, 17 studies).
Patients presenting with events in both territories had a higher risk of
stroke than those with carotid events alone (OR=2.0, 95%CI 1.3–3.1,
p=0.02, six studies) or VB events alone (OR=2.9, 95%CI 1.8–4.8,
p=0.0008, six studies). There was no significant heterogeneity
between studies for any of these results, and no differences between
prospective and retrospective studies or studies with different diagnos-
tic criteria.
Compared with patients presenting with carotid TIA or minor stroke,
patients with VB events have a slightly lower risk of recurrent stroke,
but the same risk of death and approximately twice the risk of TIA.
There is no evidence to justify less aggressive preventive treatment.
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23 HAEMODYNAMIC DETERMINANTS OF CAROTID
PLAQUE INSTABILITY
Lovett JK, Rothwell PM Stroke Prevention Research Unit, Radcliffe Infirmary,
Oxford, UK
Plaque rupture is the main cause of acute coronary events and an
important cause of ischaemic stroke. Haemodynamic forces, such as
shear stress and pulse pressure (PP), are important in early plaque for-
mation, but little is known about their effects on mature plaque. To
determine whether haemodynamic forces affect plaque stability we
studied the relationships between plaque rupture and the various com-
ponents of blood pressure (BP – PP, DBP, SBP, MAP), and between the
direction of blood flow (and hence the site of maximum shear stress)
and the site of plaque rupture.
We studied angiograms of 3007 recently symptomatic carotid
stenoses from the European Carotid Surgery Trial. We have shown
previously that assessment of angiographic ulceration is reproducible
and predicts stroke. The presence and position (relative to the point of
maximum stenosis) of any ulceration was assessed, and correlated
with the components of BP after correction for stenosis, age, sex,
diabetes and smoking.
More ulceration occurred in the proximal (v distal) part of the
plaque, where shear stress is highest (OR=7.2, 95% CI=5.6–9.5,
p<0.001). PP was the strongest independent predictor of ulceration
(OR per SD=1.20, 95% CI=1.05–1.39, p=0.01). The relationship
was weaker for SBP and MAP, and absent for DBP (OR per SD=1.08,
95% CI=0.94–1.25, p=0.2).
Haemodynamic forces, such as shear stress and PP, do appear to
be important in the rupture of mature carotid plaque. These results
suggest that, in patients with large vessel disease, treatment of BP
should take particular account of PP.
24 IMAGING UNSTABLE CAROTID PLAQUES WITH
18FLURODEOXYGLUCOSE POSITRON EMISSION
TOMOGRAPHY
Warburton EA, Rudd JHF, Fryer TD, Jones HA, Gillard JH, Antoun NA,
Kirkpatrick PJ Weissberg PL, Addenbrooke’s Hospital, Cambridge, UK
Background: There is increasing evidence that rupture of carotid
plaques causing transient ischaemic attacks (TIAs) and is the
consequence of plaque formation. Current imaging techniques
provide mainly structural information about the degree of carotid ste-
nosis. The glucose analogue 18F-flurodeoxyglucose (18FDG) is taken up
by activated inflammatory cells and can be used to image such activ-
ity by positron emission tomography (PET). This study used this form of
imaging to identify inflammation in patients with symptomatic carotid
stenotic plaques.
Patients, methods, and results: Eight patients with carotid terri-
tory TIAs awaiting endarterectomy were imaged using 18FDG-PET.
Images were coregistered to computed tomography (CT). Six of the
eight patients had contralateral asymptomatic lesions. Symptomatic
carotid plaques were clearly visible in 18FDG-PET images acquired
three hours post 18FDG injection. The net 18FDG accumulation rate
(plaque/integral plasma) in symptomatic lesions was on average
1.6631025 ±20.3531025 (95% CI 0.77–2.5531025) higher than
in contralateral asymptomatic lesions (p=0.005). There was no
measurable 18FDG uptake into normal carotid artery (artery/plasma
ration 1.0 ±20.1). Autoradiography of excised plaques confirmed
accumulation of 3H-deoxyglucose in macrophage-rich areas of the
plaque.
Conclusions: This study demonstrates that 18FDG is taken up
into carotid plaques and that symptomatic unstable plaques
accumulate significantly more 18FDG than asymptomatic lesions.
This may herald a new approach to carotid imaging that reflects that
cellular pathology of atheroma rather than its anatomical conse-
quences.
25 INHIBITION OF TRIGEMINOVASCULAR NOCICEPTIVE
TRANSMISSION BY A1 RECEPTOR AGONISTS IN THE CAT
Goadsby PJ, Hoskin KL, Storer RJ, Edvinsson L, Connor HE Institute of Neu-
rology, London, UK
Introduction: Interest in the fundamental mechanisms underlying
headache, particularly the pathophysiology of migraine and
cluster headache, has led to the study of the physiology and
pharmacology of the trigeminovascular system. The triptans,
5-HT1B/1D agonists, were substantial advances for many patients.
They have both vasoconstrictor and neuronal mechanisms of action.
The literature suggests that adenosine receptor agonists may have
anti-nociceptive effects without any vasoconstrictor action. We sought
to explore any potential role in trigeminovascular nociceptive
transmission.
Methods: Cats were anaesthetised (a-chloralose 60 mg/kg, intra-
peritoneally and, in addition, halothane for all surgical procedures).
The superior sagittal sinus (SSS) was isolated from underlying
cortex and stimulated electrically after the animals had been
paralysed with gallamine (6 mg/kg, intravenously). Units linked to
stimulation were recorded with a tungsten-in-glass microelectrode
placed in the trigeminocervical complex. Signals from the neurons
were amplified, filtered and passed to a microcomputer for analysis.
Blood was sampled from the external jugular vein to determine levels
of calcitonin gene-related peptide (CGRP) release before and after
drug administration.
Results: Units responded to SSS with a typical latency of 8–10 ms.
Intravenous administration of the highly selective adenosine A1 recep-
tor agonist GR79236 (3, 10, 30 and 100 mg/kg) had a
dose-dependent inhibitory effect on SSS evoked trigeminal neuronal
activity. The maximal effect was seen at 100 mg/kg with an 80 ± 6%
reduction in probability of firing. The inhibitory effect could be
substantially reversed by the selective A1 receptor antagonist DPCPX
(300 mg/kg iv; p<0.05). SSS stimulation increased cranial CGRP lev-
els from 33 ± 2 pmol/l to 64 ± 3 pmol/l, an effect blocked by
pretreatment with 30 mg/kg iv GR79236 (44±3 pmol/l, n=6;
p<0.01).
Conclusion: It can be concluded that in two models of trigemino-
vascular nociceptive activation after SSS stimulation the A1 receptor
agonist GR79236 showed potent inhibitory activity. These studies
suggest the adenosine A1 receptor as a novel, non-vasoconstrictor tar-
get for the development of acute antimigraine treatments.
26 DROPPED HEAD SYNDROME: THE DIFFERENTIAL
DIAGNOSIS
Nicholas RS, Lecky BRF The Walton Centre for Neurology and Neurosur-
gery, Liverpool, UK
Dropped head syndrome (DHS) is a disorder presenting with focal
failure of neck extension that is usually found in elderly patients. The
aetiology is variable with both primary neuromuscular and
extra-pyramidal causes.
We describe 12 patients that presented with DHS who were
investigated over a period of 5 years. The age of onset was
64 years (range 52–78 years), eight were women and four men. The
eventual diagnoses after full investigation included: myotonic
dystrophy (one patient), polymyositis (three patients), myopathy with
rimmed vacuoles (one patient), myasthenia gravis (two patients),
paraneoplastic motor neuronopathy (one patient), motor neuron
disease (two patients), multisystem atrophy (one patient) and probable
progressive supra-nuclear palsy (one patient). Of the three patients
with polymyositis, two had concurrent malignancies all were success-
fully treated with steroids. Both patients with myasthenia gravis
responded to steroids.
In all of these cases of DHS a precise diagnosis was made. Even in
the elderly this syndrome is worth investigating as many have treatable
pathology.
27 HEALTH, DISABILITY AND DEATH: A NEW SPECTRUM OF
DISEASE FOR HOMOPLASMIC MUTATIONS OF
MITOCHONDRIAL DNA
McFarland R, Taylor RW, Chinnery PF, Lightowlers RN, Turnbull DM
University of Newcastle upon Tyne, UK
One of the cardinal features ascribed to pathogenic mutations of
mitochondrial DNA (mtDNA) is that of heteroplasmy, a situation
where both wild type and mutant copies of mtDNA coexist within
a cell or tissue. Notable exceptions include the mutations causing
single sensory organ impairment such as Leber’s hereditary optic
neuropathy (LHON) and aminoglycoside induced deafness (AID). In
both of these conditions, homoplasmic mutations (where all copies of
the mtDNA are mutant) cause disease. To date, there have been no
reports of homoplasmic mutations resulting in lethal multisystem disor-
ders.
We describe three different pathogenic homoplasmic mutations in
families from North East England. The dichotomous phenotype associ-
ated with both LHON and AID is starkly contrasted against these fam-
ily histories of healthy individuals, neonatal and early childhood
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deaths and progressive neurodisability. All of these mutations occur in
mitochondrial tRNA genes, fulfil other accepted criteria for
pathogenicity and are supported by striking biochemical, histological
and steady state tRNA data.
At present these homoplasmic mutations represent a small but
significant proportion of patients and their contribution to mito-
chondrial disease should not be overlooked. Indeed, they raise ques-
tions regarding the true incidence of mtDNA disease in the
population. Furthermore, explaining the mechanisms behind the
extreme phenotype variability will enhance our understanding of the
whole field of mitochondrial genetics.
28 EARLY ONSET FAMILIAL ALZHEIMER’S DISEASE:
MUTATION FREQUENCY IN 31 FAMILIES
Janssen JC, Beck JA, Campbell TA, Dickinson A, Fox NC, Harvey RJ, Houl-
den H, Rossor MN, Collinge J Institute of Neurology, London, UK
Background: Three causative genes have been identified for
autosomal dominant Alzheimer’s disease (AD): the amyloid precursor
protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes.
In addition a risk gene for AD has been identified: the apolipoprotein
E gene.
Methods: A mutational analysis of these genes was performed in
31 probands with probable or definite AD from UK families with an
age at onset <61 years.
Results: The median age at onset was 45 years (range: 33–60
years). Twenty three probands had family histories consistent with
autosomal dominant inheritance. In 17 probands 16 PSEN1 mutations
were identified, including a novel three base pair deletion mutation
which effectively deletes codon 167 (?167) and seven novel missense
point mutations (Y154C, I229F, F237L, L253V, C263F, R377M and
G378V). In three probands mutations in APP were identified,
including a novel mutation at codon 715 (V715A). Mutations in
PSEN1 and APP were present in 78% of autosomal dominant AD and
25% of patients who did not fulfil criteria for autosomal dominant
inheritance. Eleven patients did not have a pathogenic mutation in
APP, PSEN1, or PSEN2, these probands were older than those in
whom mutations were demonstrated (54.0 v 44.0 years: p=0.001)
and had an APOE e4 allele frequency of 0.72.
Conclusions: Mutations in APP and PSEN1 account for the major-
ity of early onset autosomal dominant AD. The patients without a
causative mutation were significantly older and had a higher APOE
e4 allele frequency than the general white population suggesting
familial clustering due to the presence of this risk gene.
29 THE EFFECT OF EPILEPSY ON THE BRAIN: FINDINGS OF
A LONGITUDINAL COMMUNITY BASED QUANTITATIVE
MRI STUDY
Liu RSN, Lemieux L, Bell GS, Sisodiya SM, Bartlett PA, Sander JWAS,
Shorvon SD, Duncan JS Institute of Neurology, London
Background: The question of whether epilepsy causes cerebral dam-
age remains unanswered. We report the first community-based quan-
titative MRI study investigating the longitudinal effect of seizures.
Methods: Serial MRI brain scans were performed on 190 epilepsy
patients, recruited prospectively from a local population of 207 553.
Patients with chronic active epilepsy (122), new onset seizures (68),
and age matched controls (90) were scanned 3.5 years apart.
Manual, semiautomated, and automatic regional brain volume meas-
urements were performed on coregistered image pairs. The investiga-
tor was blinded to subject status and the chronological order of each
scan pair. Longitudinal volume changes were studied in three age
epochs (<35, 35–54, >54 years).
Results: Controls aged 35–54 and over showed brain atrophy,
primarily due to white matter loss. Increased rates of hippocampal
atrophy were seen over 54 years. Six of 68 newly diagnosed and 24
of 122 chronic epilepsy patients demonstrated significant volume
changes. Within group analyses revealed significant hippocampal,
cerebellar, white matter and total brain volume losses in both patient
cohorts. Seizure frequency, number of AEDs and epilepsy syndrome
were not significantly correlated with brain atrophy.
Discussion: Aging exerts differential effects on regional brain vol-
umes. Nine per cent of newly diagnosed patients and 20% of patients
with chronic epilepsy had significant volume loss; however seizures
do not inevitably lead to cerebral damage.
30 THE WREXHAM AREA EPILEPSY PROJECT
Leach JP, Bartolo R, Nicolson A, Smith DF Wrexham Maelor Hospital and
The Walton Centre for Neurology, UK
An increasing proportion of patients with epilepsy are diagnosed by
neurologists. However, there is a large reservoir of patients with this
label who have never seen a specialist. Our aim was to describe a
sample of such patients living in the catchment of a District General
Hospital.
All adults with epilepsy, on treatment, not attending an epilepsy
clinic, identified from the records of 34 practices in the Wrexham
area, were invited to attend for review of their condition
The first 200 patients are reported. The misdiagnosis rates for those
diagnosed by non-specialists and neurologists were 21.3% and 6%
respectively. The remission rates in patients with partial and idiopathic
generalised epilepsies were 55 and 50% respectively, the latter being
poorer than expected. The proportion of patient’s offered, and accept-
ing, change of treatment were 63 and 42% respectively. Irrespective
of seizure control many patients were seeking specific information.
Even in an area with an established epilepsy clinic there is consid-
erable unmet need. More than 40% of patient’s will accept specialist
follow up and an additional 10–20% would benefit from nurse coun-
selling. This cross sectional data should inform future service develop-
ments.
31 CEREBRAL METABOLITE AND NEUROTRANSMITTER
CONCENTRATIONS IN IDIOPATHIC GENERALISED
EPILEPSY MEASURED WITH SHORT ECHO TIME PROTON
MR SPECTROSCOPY
Simister RJ, McLean MA, Barker GJ, Duncan JS Institute of Neurology, Lon-
don, UK
Background: Glutamate is the most important excitatory transmitter
and γ-amino butyric acid (GABA) the dominant inhibitory neurotrans-
mitter in the neocortex. We have developed proton MR spectroscopy
(MRS) methods for reliably measuring GABA and the glutamate plus
glutamine signal complex (GLX) in vivo. We now report on measure-
ment of these metabolites in patients with idiopathic generalised epi-
lepsy (IGE).
Methods: 25 patients with a diagnosis of IGE and normal MRI
imaging and 18 normal control subjects were studied. All scans were
performed on a 1.5T GE scanner. One voxel was prescribed (approx
35 ml) in each frontal lobe for each subject. N-acetyl aspartate (NAA)
and GLX were measured by performing short echo time PRESS local-
ised MRS whilst GABA measurement was via our double quantum
GABA filter.
Results: Comparison was made between IGE and control groups.
The right (R) and left (L) voxels were considered separately. The main
findings were low NAA (R: p<0.01, L: p=0.08) and high GLX (R:
p=0.08,L: p<0.05) in the IGE group. No group differences were
observed for GABA.
Discussion: This is the first MRS study of GLX and GABA concen-
trations in IGE. The major finding of increased GLX suggests that
abnormality in glutamate regulation and leading to intracellular accu-
mulation could be a factor in IGE. Low NAA may well reflect subtle
levels of neuronal dysfunction, despite normal MRI.
32 POSTERIOR MESIAL TEMPORAL LOBE EPILEPSY: A
DISTINCT SYNDROME?
Wieshmann UC, Denby CE, Eldridge PR, Chadwick DW, Roberts N
University of Liverpool, UK
Background: We propose a posterior mesial temporal lobe epilepsy
(TLE) syndrome that is indistinguishable clinically from anterior TLE, but
less amenable to epilepsy surgery.
Methods: We compared the presurgical T1 weighted magnetic
resonance images of a group of TLE patients who became seizure free
after resection of anterior mesial temporal structures (n=18) with a
group of TLE patients who continued to have seizure after this opera-
tion (n=13) using statistical parametric mapping.
Results: We found a reduction in grey matter density in the poste-
rior part of the temporal lobe (the occipito temporal gyrus) in surgical
failures. This abnormality was ipsilateral to the resection but beyond
the resection margin.
Discussion: Posterior and anterior mesial TLE appear to have iden-
tical clinical, electrical and structural features including mesial tempo-
ral sclerosis and specific tests to identify patients with posterior mesial
epilepsy may be necessary to avoid unsuccessful epilepsy surgery.
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33 TRANSIENT MONOCULAR BLINDNESS DUE TO
VASOSPASM: VIDEO RECONSTRUCTION OF THE
RETINAL VASCULATURE DURING AN ATTACK
Petzold A, Islam N, Plant GT Moorfields Eye Hospital; The National Hospi-
tal for Neurology and Neurosurgery; Institute of Neurology, London, UK
Background: Transient monocular blindness (TMB) may be due to
vasospasm embolism or other factors affecting retinal perfusion. Reti-
nal vasospasm responds to calcium channel blockers.
Methods: Case presentation
Results: A 25 year old male patient presented with a 3 day history
with about 40 episodes of loss of vision in the left eye. Each episode
started with a 30 seconds to 1 minute phase where the vision slowly
dimmed away. After 1 to 5 minutes of complete blindness (with
absence of the direct pupil light reflex) vision returned over about 30
seconds. Recovery was always complete. Fundus examination during
an attack showed narrowing of the central retinal artery and
branches, retinal pallor and very slow flow with “cattle trucking” in the
retinal venules. Sequential photographs of the fundus were obtained
immediately after the onset of such an attack. The photographs were
used to construct an animation which demonstrates for the first time the
dynamics of the retinal vasculature during TMB due to vasospasm. The
patient was treated with 80 mg/day nifedipine and no further
episodes occurred during the 6 months follow up.
Discussion: Retinal vasospasm should carefully be sought for dur-
ing diagnostic investigation of patients with TMB, particular if the epi-
sodes occur frequently. If TMB continues to occur after antithrombotic
treatment and there is no evidence of embolism a trial with Ca-channel
blockers would be recommended before subjecting the patient to more
invasive procedures.
34 A SUCCESSFUL DOMICILLARY TREATMENT FOR
PATIENTS WITH HOMONYMOUS HEMIANOPIA
Pambakian ALM, Mannon SK, Hodgson TL, Kennard C Imperial College
School of Medicine; Charing Cross Hospital, London, UK
Patients with homonymous hemianopia (HH) are disabled because
they cannot scan the visual world effectively. We have therefore
devised a simple rehabilitation tool based on a visual search (VS)
paradigm. We hypothesised that by training hemianopes to adopt
more efficient eye movement strategies into their blind field, their
searching will improve and their disability reduce. The equipment is
uniquely portable, low cost and easy to deploy by therapists naïve to
the technique of VS. Patients can therefore be treated at home, caus-
ing minimal disruption to their daily lives.
Twenty nine hemianopes (15 L, 14 R) were treated at home under
supervision. They practised 6 VS paradigms in 20 daily sessions last-
ing 40 minutes over 1 month. We examined their response times (RT)
before and after training to determine whether they develop compen-
satory eye movement strategies with improvements in their overall
function, measured objectively using tasks representing activities of
daily living (ADL), and subjectively using a visual disorder
questionnaire.
Patients improved in VS by adopting one of three strategies: Most
(22) showed shorter mean RT, (ANOVA p<0.0001). Three patients
with high error rates (>20%) showed longer RT which improved with
training in a complex speed accuracy trade off, (ANOVA p<0.0001).
Four showed no significant change in response time but had
significant training effects with high level hemifield interactions.
These represent specific and robust training effects, with accompa-
nying improvements in ADL performance and questionnaire scores,
but no concomitant visual field enlargement.
35 HIGH FREQUENCY SACCADIC OSCILLATIONS ARE
GENERATED BY BRAIN STEM, NOT CEREBELLAR,
NEURONS
Leigh RJ, Ramat S, Zee DS, Optican LM Case Western Reserve University,
Cleveland, Ohio; Johns Hopkins University, Baltimore; National Eye
Institute, Bethseda, USA
Objective: To determine whether saccadic oscillations, such as opso-
clonus, arise primarily from the brainstem or cerebellar circuits.
Methods: We measured visually guided saccades and saccadic-
vergence movements in a patient with a midline surgical lesion that
included both fastigial nuclei, and in five age-matched control
subjects, using the magnetic search coil technique. We tested a
current model for saccade generation, which includes brainstem sac-
cadic burst neurons, and feedback control via the fastigial nucleus.
Results: The patient’s visually guided saccades showed bilateral,
horizontal hypermetria, and prolonged deceleration phase, consistent
with experimental bilateral inactivation of the fastigial nucleus. During
combined saccadic-vergence movements, the patient and control sub-
jects all showed small-amplitude, high-frequency (20–35 Hz),
conjugate horizontal oscillations of the eyes during the vergence
movement that followed the initial saccade. The model predicted that,
since feedback control of saccade trajectory by the fastigial nucleus
was impaired in the patient, the high-frequency conjugate oscillations
were generated by excitatory and inhibitory brainstem burst neurons
which are configured in positive feedback, with high gain for small
movements.
Conclusions: These findings suggest that high-frequency saccadic
oscillations, as well as pathological flutter and opsoclonus, are gener-
ated by local brainstem connections between burst neurons, and occur
when omnipause neurons are inhibited.
36 DETECTION OF ASYMPTOMATIC LACUNAR INFARCTS
WITH DIFFUSION WEIGHTED MRI: A POTENTIAL
SURROGATE MARKER OF DISEASE ACTIVITY IN
ISCHAEMIC LEUKOARAIOSIS AND CADASIL
O’Sullivan M, Rich PM, Barrick TR, Clark CA, Markus HS Division of Clini-
cal Neuroscience, St. George’s Hospital Medical School, London, UK
Background: Cerebral small vessel disease is an important cause of
cognitive impairment. It is usually sporadic but also occurs in the auto-
somal dominant disorder CADASIL. Recurrent lacunar stroke
contributes to disease burden but symptomatic events are relatively
rare, making large numbers necessary for clinical trials. Surrogate
markers may have a role in screening therapies for efficacy. Diffusion
weighted imaging (DWI) is sensitive to acute ischaemia and differen-
tiates acute from chronic lacunar infarcts. If asymptomatic lesions were
more common than symptomatic lesions they would be a potentially
useful surrogate marker, analogous to detection of enhancing lesions
as a marker in MS.
Methods: Fifty patients with sporadic small vessel disease and 19
with CADASIL underwent DWI. All had been asymptomatic for 3
months before imaging. DWI were screened by two raters; new
lesions were confirmed as recent by a visible reduction of mean diffu-
sivity on mean diffusivity maps.
Results: Recent ischaemic lesions were identified in four patients
with sporadic small vessel disease (8.0%) and two with CADASIL
(10.5%). Estimated lesion frequencies were one every 125–175 days
in the sporadic group and one every 95–133 days in CADASIL.
Conclusions: DWI detects asymptomatic new lesions with
sufficient frequency to suggest a role as a surrogate marker of disease
activity in sporadic small vessel disease and CADASIL.
37 DOES DIFFUSION WEIGHTED IMAGING ALTER
MANAGEMENT IN PATIENTS WITH SUBACUTE MINOR
STROKE AND TIA?
Schulz U, Briley D, Meagher T, Molyneux A, Rothwell PM Stroke Prevention
Research Unit, Radcliffe Infirmary, Oxford, UK
Diffusion weighted brain imaging (DWI) is used in acute stroke, but
may also be useful in patients with minor stroke or TIA when seen sev-
eral days or weeks after symptom onset. Although visualisation of an
acute ischaemic lesion, and knowledge of the number of lesions, and
their territory(s), could influence management, there are no published
studies.
119 consecutive TIA clinic patients who were considered likely to
have had a cerebral ischaemic event underwent T2-weighted and
DWI MR scanning. Two independent observers (neurologist and neu-
roradiologist) first reviewed the T2 images and then both the T2 and
DWI scans. We assessed the frequency and certainty with which
acute lesions were noted, and how often DWI provided additional
clinically useful information.
DWI showed a recent lesion in 37 (60%) of 62 patients with minor
stroke and 8 (14%) of 57 patients with TIA. Among 44 patients with
symptoms <2 weeks, DWI was positive in 18/27 (67%) strokes and
3/17 (18%) TIAs. Among 75 patients presenting >2 weeks, DWI was
positive in 19/35 (54%) strokes and 5/40 (13%) TIAs. In 27 (44%)
patients with stroke and 8 (14%) with TIA, DWI provided additional
clinically useful information. Inter-observer agreement for the
identification of acute lesions was higher on DWI than on T2
(kappa=0.94 v 0.49, p<0.01).
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DWI is often positive several weeks after a minor stroke or a TIA.
Interobserver agreement for the identification of acute lesions is higher
than on T2, and DWI frequently provides additional clinically useful
information that changes management. This suggests that combined
T2 and DWI should be the imaging protocol of choice for patients with
subacute minor stroke or TIA.
38 IMPAIRED SPATIAL MEMORY CONTRIBUTES TO
UNILATERAL NEGLECT
Husain M, Mannan S, Mort D, Hodgson T, Driver J, Kennard C Imperial
College School of Medicine, Charing Cross Hospital, London, UK
Right hemisphere stroke patients with unilateral neglect ignore stimuli
to the left in everyday life, as well as on bedside tests that require them
to search for visual objects. Such left neglect may reflect a bias to
direct attention rightwards. We hypothesised that neglect may also
involve a failure to remember locations that have been searched
before.
We monitored eye position during visual search in 24 right
hemisphere stroke patients (eight with severe left neglect; eight with
mild neglect; and eight without neglect), as well as 16 healthy control
subjects. We probed spatial memory during search by asking subjects
to press a response button whenever they found a new target. They
were asked not to press if they refixated a target they had previously
judged to be new.
Eleven neglect patients demonstrated significantly impaired spatial
memory, recursively re-examining stimuli on the right and, critically,
failing to remember previously searched locations. High resolution
MRI demonstrated that impaired spatial memory was associated with
damage to discrete locations in the inferior parietal and inferior fron-
tal lobe.
The degree of neglect correlated significantly with the spatial
memory impairment. Treatments that target the memory deficit may
therefore offer opportunities for reducing the severity of neglect.
39 PERIODIC PARALYSIS, MALIGNANT VENTRICULAR
ARRHYTHMIA AND DYSMORPHISM (ANDERSEN’S
SYNDROME): A SKELETAL MUSCLE POTASSIUM
CHANNEL DISORDER
Davies NP, Weber A, Mueller R, Hilton-Jones D, Chinnery PF, Hanna MG
Institute of Neurology, London, UK
Background: Andersen’s syndrome is a triad of periodic paralysis
(hypo or hyper), malignant ventricular arrhythmias and dysmorphism.
The syndrome is often overlooked as the dysmorphism is subtle and the
ventricular arrhythmias may not become symptomatic until later in the
disease course. Mutations in a voltage independent skeletal muscle
potassium channel gene (KCNJ2) were recently shown to cause this
disorder.
Methods: We identified three families with clinical features
consistent with Andersen’s syndrome. In addition to detailed clinical
examination each patient underwent neurophysiological and cardio-
logical investigations. Molecular genetic analysis of each proband
was performed by direct DNA sequencing of the entire coding region
of KCNJ2. Control chromosomes (160) were screened using
restriction digests.
Results: Each family harboured a new pathogenic point mutation
within KCNJ2. In family A, an aspartic acid was substituted for a gly-
cine at codon (G300D) in the carboxy terminal of the channel. Family
B and C harboured mutations in the amino terminal (D78G, R67W).
Conclusion: Andersen’s syndrome should be considered in any
patient with hypo or hyperkalaemic periodic paralysis. The ventricular
arrhythmias may post date the onset of the paralytic episodes by years
but the ECG often shows a long QT interval early on in the disorder.
We have identified 3 new disease-causing mutations in KCNJ2, dem-
onstrating that DNA-based diagnosis is possible in this disorder. It is
important to note that non-penetrance occurs in this disorder and there
is a high de novo mutation rate.
40 EVIDENCE FOR UNDERDIAGNOSIS OF MYASTHENIA
GRAVIS IN THE ELDERLY
Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM Institute of
Molecular Medicine, John Radcliffe Hospital, Oxford; Radcliffe Infirmary,
Oxford, UK
Background: Myasthenia gravis (MG) can be confirmed by a
positive acetylcholine receptor (AChR) antibody test, but the diagnosis
can be missed in older patients. We looked for evidence of
underdiagnosis of MG in the UK.
Methods: We identified positive AChR antibody tests in the UK
during 1997–99 from all UK centres registered with the European
Quality Assurance Scheme (EQAS), and calculated the age and sex
specific incidence. We tested sera from 1127 elderly individuals,
from the Oxford region, aged >75 years.
Results: From the UK data, we identified 3183 positive AChR anti-
body tests giving an incidence of 1.8 cases/100 000/year. In both
sexes, age specific incidence rose sharply between the ages of 55
and 70, plateaued at >70 years, and then fell sharply above 80
years. In our elderly cohort, aged >75 years, eight sera (0.70%) were
positive for AChR antibodies. Only one of these individuals had had a
previous clinical diagnosis of MG.
Discussion: The plateau and then fall over 75 years in the age
specific incidence, together with the high prevalence of positive AChR
antibody in the >75 year olds, suggests that myasthenia gravis is
indeed under-diagnosed in the elderly. The results highlight the need
for a high index of suspicion for this treatable disease.
41 CHARACTERISATION OF THE CELL DEATH PATHWAY IN
A CELLULAR MODEL OF FAMILIAL MOTOR NEURON
DISEASE
Sathasivam S, Menzies FM, Cookson MR, Grierson AJ, Shaw PJ University
of Sheffield, UK
Background: Motor neuron disease (MND) ia a rapidly progressive
neurodegenerative disorder, primarily affecting the upper and lower
motor neurons. Around 10% of MND cases are familial, of which one
fifth are associated with mutations in the gene encoding the free radi-
cal scavenging enzyme copper/zinc superoxide dismutase-1 (SOD1).
There is mounting evidence that the final motor neuron cell death path-
way in MND is a programmed mechanism of cell death resembling
apoptosis. The aim of this study was to characterise the sequential
activation of molecular components in the apoptotic cell death
pathway in a cell culture model of motor neuron injury induced by the
presence of mutant SOD1 under basal conditions and or oxidative
stress.
Methods: Using a motor neuron cell line (NSC34) stably
transfected with mutant or normal forms of human SOD1, or with a
vector alone, we examined the cell death pathway under conditions of
oxidative stress induced by serum withdrawal. Initially we have exam-
ined biochemical and morphological indices of apoptosis, including
expression of phosphotidylserine at the cell surface, nuclear fragmen-
tation, and activation of caspases, a group of protease enzymes
which are molecular effectors of apoptosis.
Results: Under basal conditions, cells containing mutant G93A
SOD1, compared to cell transfected with normal SOD1 or vector only,
showed changes suggesting an increased propensity to apoptosis,
including activation of caspase 9 (p<0.0001 by two way ANOVA)
and externalisation of phosphotidylserine. When subjected to
oxidative stress, the presence of mutant SOD1 resulted in a greater
than 70% fall in cell viability compared to cells transfected with vector
only. In addition, there was significantly increased activation of
caspase 3 in the presence of mutant SOD1 in cells induced to undergo
oxidative stress compared to control cell groups (p<0.0001 by two
way ANOVA).
Conclusion: The presence of mutant SOD1 causes increased
expression of molecules known to play a role in apoptotic cell death
and an increased likelihood of neuronal cell death in the presence of
oxidative stress.
42 PROTEOMIC ANALYSIS OF PROTEIN ALTERATIONS IN A
CELL CULTURE MODEL OF FAMILAL MOTOR NEURON
DISEASE
Shaw PJ, Allen S University of Sheffield, UK
Background: Mutations in the gene encoding Cu/Zn superoxide dis-
mutase (SOD1) account for 20% of cases of familial motor neuron dis-
ease (MND). There is evidence that motor neuron (MN) injury results
from a toxic gain of function of mutant SOD1, but the precise mecha-
nisms of cell specific neurodegeneration have not yet been identified.
Identification of MN protein changes occuring in the presence of
mutant SOD1 is likely to shed light on important molecular
mechanisms underlying cellular injury.
Aims: The aims of this study were to investigate the effects of
mutant SOD1 on expression levels and post-translational modification
of cellular proteins in a cell culture model of familial MND, using a
proteomic approach.
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Methods: A robust cell culture model of familial MND has been
developed using a motor neuron cell line (NSC34) stably transfected
to express normal or mutant forms (G93A, G37R) of human SOD1.
Subcellular fractionation allows proteins in different cell compartments
to be analysed and we have focused intitally on the cytosolic fraction.
Cytosolic proteins from this cell model were subjected to two
dimensional gel electrophoresis which allows proteins to be separated
first on the basis of electric charge and then by molecular weight. Cells
expressing mutant forms of SOD1 were compared to control cells
expressing normal SOD1 or cells transfected with vector only. Protein
spots were visualised by silver staining and changes in protein expres-
sion analysed using Phoretix 2D software. Protein spots that increased
or decreased in the presence of mutant SOD1 compared to control
cells at a confidence level of p<0.05 (using two tailed Wilcoxon non-
parametric paired t test) were selected for identification. Protein spots
of interest were excised and analysed by MALDI-TOF mass spectrom-
etry. The resulting peptide mass profile allowed protein identification
using an MS-fit database search.
Results: Spots representing 750 cytosolic proteins could be
reliably identified from the NSC34 cells. In the presence of mutant
SOD1, significant changes in the expression of nine proteins were
identified. Four of these proteins showed a greater than twofold
increase in expression and five proteins were down regulated.
MALDI-TOF analysis combined with protein data base searching has
to date allowed the identification of five of these proteins.
Confirmation of the changed expression was obtained by undertaking
western blotting with antibodies specific to the candidate proteins on
homogenates of the NSC34 cells. The identified proteins fall into four
categories and are involved in pathways likely to be highly relevant to
motor neurone degeneration. These include proteins involved in nitric
oxide metabolism; nucleotide metabolism; protein degradation
pathways and cytosolic redox regulation.
43 DETECTION OF MUSK ANTIBODIES IN SERONEGATIVE
MYASTHENIA GRAVIS USING HUMAN MUSK AS
ANTIGEN
McConville J, Hoch W, Beeson D, Newsom-Davis J, Vincent A Institute of
Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Background: Seronegative myasthenia gravis (SNMG), in which
acetylcholine receptor antibodies cannot be detected, constitutes 20%
of generalised and 50% of ocular myasthenia gravis. We have
recently discovered that the muscle specific kinase, MuSK, is a target
for autoantibodies in SNMG. Using rat MuSK extracellular domains in
an ELISA, we detected MuSK antibodies in 70% of generalised
SNMG (Hoch et al 2001). It was possible that the rat MuSK ELISA
lacked sufficient sensitivity to detect all MuSK antibodies.
Methods: To obtain human MuSK protein for further studies, we
cloned human MuSK and expressed the native protein in the human
embryonic kidney (HEK293) cell line. We used the fluorescence acti-
vated cell sorter to detect antibody binding to the cells.
Results: All SNMG samples positive for antibodies to rat MuSK
were also positive with human MuSK but 30% of generalised SNMG
patients continued to be seronegative for both AChR and MuSK anti-
bodies. We did not detect MuSK antibodies in pure ocular MG.
Discussion: Our results confirm the presence of MuSK antibodies
in up to 70% of SNMG patients. The target of the antibodies in the
remaining SNMG patients needs to be defined.
44 RANDOMISED DOUBLE BLIND TRIAL OF METHOTREXATE
AND STEROIDS COMPARED WITH AZATHIOPRINE AND
STEROIDS IN THE TREATMENT OF IDIOPATHIC
INFLAMMATORY MYOPATHY
Miller JAL, Walsh Y, Saminaden S, Lecky BRF, Winer JB University Hospi-
tal Birmingham, UK
Background: The idiopathic inflammatory myopathies are a group
of immune-mediated disorders characterised by muscle weakness and
lymphocytic infiltrate in striated muscle. Corticosteroids form the main-
stay of treatment with immunosuppressive treatment frequently used as
an adjunct to reduce the long-term requirement for steroids. No
randomised controlled trials have compared different immunosuppres-
sive treatments. Rheumatological practice favours the use of
methotrexate while azathioprine is often used by neurologists.
Methods: We have undertaken a randomised double blinded pla-
cebo controlled trial in 28 patients with either polymyositis or
dermatomyositis. Subjects received prednisolone plus either azathio-
prine 2.5 mg/kg daily or methotrexate 15 mg weekly. The primary
end point of the study was the change in hand held myometry
readings at the end of one year. Secondary endpoints were changes
in timed walks, final steroid dose, and side effects of treatment.
Results: These are given in the table.
Discussion: Azathioprine and methotrexate had equivalent effi-
cacy as adjunctive treatment but the better side-effect profile of metho-
trexate would suggest this to be the preferred agent in the treatment of
idiopathic inflammatory myopathy.
45 HOW MUCH DO NEURORADIOLOGISTS AGREE IN
THEIR ASSESSMENT OF ANGIOGRAMS OF
ARTERIOVENOUS MALFORMATIONS OF THE BRAIN?
IMPLICATIONS FOR MANAGEMENT
Al-Shahi R, Pal N, Lewis SC, Bhattacharya JJ, Sellar RJ, Warlow CP
Department of Clinical Neurosciences, University of Edinburgh, Edinburgh,
UK; Institute of Neurological Sciences, Southern General Hospital,
Glasgow, UK
Background: The vascular anatomy (angioarchitecture) of brain
arteriovenous malformations (AVMs) demonstrated on intra-arterial
digital subtraction angiograms is thought to influence their prognosis,
and is used by interventionists to decide whether and how to treat an
AVM. But are neuroradiologists consistent in their description of
angioarchitecture?
Methods: Five experienced neuroradiologists independently re-
viewed a selection of 40 anonymised angiograms from the time of
first-ever AVM diagnosis, on two separate occasions. They assessed
16 separate features on the angiograms. We measured intra and
interobserver agreement with the kappa statistic (k) for nominal data
(eg, presence of aneurysms), weighted k for ordinal and discrete inter-
val data (eg number of feeding vessels), and Bland and Altman analy-
sis for continuous data (eg, nidus size).
Results: Intraobserver agreement was generally moderate to
substantial with 95% confidence intervals ranging from fair to almost
perfect. However, for every characteristic, interobserver agreement
was less than intraobserver agreement. Interobserver agreement was
generally slight to moderate, with 95% confidence intervals ranging
from less than chance to almost perfect.
Discussion: This study urges caution if relying on AVM
angioarchitecture to make management decisions, and demonstrates
the need for robust, generalisable definitions—with good observer
agreement—for future efforts to understand the prognosis and best
treatment of AVMs.
46 MECHANISMS OF IDIOPATHIC INTRACRANIAL
HYPERTENSION IN VASCULITIS PATIENTS WITHOUT
CEREBRAL VENOUS SINUS THROMBOSIS
Everitt A, Newry S, Graham E, Plant G National Hospital for Neurology
and Neurosurgery; Medical Eye Unit, St Thomas’ Hospital, London, UK
An association between systemic lupus erythematosus (SLE) and
intracranial hypertension is well recognised but rare. Cerebral venous
sinus thrombosis is identified as the underlying cause in some patients,
whilst in the majority the pathogenesis is poorly understood.
We present six patients with SLE and one with Wegener’s granulo-
matosis (WG) who presented with symptoms due to idiopathic intrac-
ranial hypertension (IIH). Five had known SLE but, in two, the
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Patients with >30%
improvement in myometry
Average improvement
in walk time (%)
Average final steroid
dose (mg)
Patients with grade
3 or 4 WHO toxicity
Azathioprine (n=12) 5 16 11 4
Methotrexate (n=16) 7 30 11 0
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development of IIH led to the diagnosis of SLE and WG, respectively.
Four patients were receiving combined oral steroids and immunosup-
pressants at presentation. Most subjects had evidence of high disease
activity (systemic symptoms, high autoantibody levels and inflamma-
tory markers. Three had recent weight gain and two had elevated
anti-cardiolipin antibodies. One patient had diffusely abnormal
cerebral white matter on MRI, but none had venous sinus thrombosis.
CSF constituents were normal except in the WG patient who had a
mild CSF lymphocytosis and elevated protein. One SLE patient subse-
quently developed cerebral lupus and died suddenly. Post mortem
examination revealed multiple small cortical and brainstem infarcts,
but no vasculitis or small vessel emboli were noted. A further SLE
patient was found to have microemboli on renal biopsy.
It seems likely that IIH associated with vasculitis is multifactorial and
may involve processes such as thrombotic obliteration of vascular
beds supplying arachnoid villi, and immune complex deposition in the
choroid plexus. Insights into the putative mechanisms of IIH from these
seven patients will be discussed.
47 A COMPARISON OF THE EFFECTS OF CAROTID
ENDARTERECTOMY AND CAROTID ENDOVASULAR
TREATMENT ON BLOOD PRESSURE IN THE ACUTE
POSTOPERATIVE PERIOD
McKevitt FM, Sivaguru A, Gaines PA, Cleveland TJ, Beard JD, Channer KS,
Venables GS Royal Hallamshire Hospital; Northern General Hospital,
Sheffield, UK
Background: Acute haemodynamic instability has been documented
after both carotid endarterctomy and carotid angioplasty and
stenting. This can result in prolonged hospital admission or neurologi-
cal complication. This study compares the effects of both procedures
on blood pressure in the first twenty-four hours following treatment.
Methods: Patients were randomised to carotid endarterectomy
(49) or endovascular treatment (55). A baseline 24 hour ambulatory
blood pressure recording was taken prior to carotid intervention and
repeated during the firstn 24 hours postprocedure. The number of
patients experiencing episodes of hypotension or hypertension was
documented.
Results: Episodes of hypotension were seen frequently in both
groups, (76% in the endovascular group and 70% in the surgical
group, p=0.50). The number of patients in each group who
experienced a hypertensive episode was also similar, (15% in the
endovascular group v 12% in the surgical group, p = 0.65).
Discussion: Blood pressure disturbances are common following
both endovascular and surgical treatment of carotid artery stenosis
however neither intervention offers a haemodynamic advantage in the
first 24 hours postprocedure.
48 ACUTE ONSET NEW VARIANT CREUTZFELD-JAKOB
DISEASE IN A COMPULSIVE JELLY EATER
Das R, Molloy J, Nisbet A Hurstwood Park Neurological Centre, Haywards
Heath, UK
A case of variant CJD (tonsillar biopsy confirmed) is presented, exhib-
iting some interesting features which may shed new light on this enig-
matic disease.
Clinical presentation: Our patient presented to her GP with
depression. She returned 3 weeks later with sudden onset numbness
and heaviness over the left side of her face. She was noted to have a
microvesicular eruption on the upper lip bilaterally. Viral antibody
titres were negative. Since presentation she has swiftly deteriorated
physically and cognitively. Dietary history revealed a habit of
excessive consumption of jelly.
Investigations: Serial MRI scans show evolution of high T2 signal
in the pulvinar and medial thalamus bilaterally, plus high signal in the
medial geniculate bodies and superior colliculi.
Discussion: The case raises three interesting points for discussion:
1) could the rapid evolution of sensory symptoms with accompanying
vesicular eruption, with negative conventional serology, represent a
seroconversion equivalent in variant CJD, related to prion protein
load? 2) the sequential MRI changes have not been seen before in this
distribution, and may represent a new neuroradiological phenotype in
this disease. 3) the potential for gelatin to carry the infective particles
may warrant closer attention—it remains a potential route of human
exposure to BSE.
49 IDENTIFICATION OF NEW PRION DISEASE
SUSCEPTIBILITY LOCI
Mead S, Mahal S, Beck J, Farall M, Fisher EMC, Collinge J Institute of
Neurology, London, UK
A common human prion protein gene (PRNP) polymorphism (encoding
either methionine or valine at codon 129) is a strong susceptibility fac-
tor for sporadic and acquired prion disease. We have analysed the
PRNP locus for tightly linked susceptibility factors. 56 polymorphic
sites have been identified within 25 kb of the PRNP open reading
frame including sites within the PRNP promoter and PRNP 39 untrans-
lated region. These have been characterised in 61 CEPH families,
demonstrating extensive linkage disequilibrium around PRNP and the
existence of eleven major European PRNP haplotypes. Haplotype fre-
quencies estimated in healthy UK controls were very similar to those
deduced in the CEPH families. A common haplotype was
overrepresented in patients with sporadic CJD. Using a log linear
modelling approach to simultaneously model Hardy-Weinberg and
linkage disequilibria, a significant independent association was found
between a polymorphism upstream of PRNP exon 1 and sporadic CJD
(p=0.005), in addition to the strong susceptibility conferred by codon
129 (p=2×10−8). Although our sample size was necessarily small, no
association was found between these polymorphisms and vCJD or
iatrogenic CJD, in keeping with their having distinct disease
mechanisms. In addition, there was no evidence of a PRNP founder
effect in the first reported geographical cluster of vCJD. We hope to
use genetic susceptibility loci like PRNP and the recently identified
vCJD resistance factor HLA-DQ7 to characterise the molecular
pathways involved in prion disease and stratify the evolving epidemic
of variant CJD.
50 THE BRITISH AND DANISH FORMS OF FAMILIAL BRI
DEMENTIA
Plant GT, Braendgaard H, Revesz T, Vidal R, Ghiso J, Frangione B National
Hospital for Neurology and Neurosurgery, London, UK and New York
University Medical Centre, New York, USA
Two enigmatic dominantly inherited familial conditions have been
shown to be due to different mutations in the same gene. One is the
disorder described by Worster-Drought in Britain in the 1930s which
he called familial pre-senile dementia with spastic paralysis. The sec-
ond originates from Jutland and was described in 1981 by Stromgren
as heredopathia ophthalmo-oto-encephalica. In the British family a
point mutation in the BRI gene results in an amyloid precursor protein
(ABriPP 277) which is 11 amino acids longer than the wild type BRI
protein (BRI 266). In the Danish family a 10 decamer nucleotide dupli-
cation gives rise to ADanPP 277. In each disorder a 34 amino acid
amyloidogenic peptide is formed (ABri and ADan); the N-terminal 22
amino acid sequences are identical whilst the C-terminal 12 amino
acids are completely different. Any differences between the two disor-
ders should be explained by different properties of ABri and ADan.
The major differences are seen below the age of 40 when Danish
cases have already developed cataract and deafness, features not
seen in the British families. From age 40 dementia, ataxia and spas-
ticity are seen in both. Pathologically both conditions show amyloid
angiopathy, cerebellar and hippocampal plaque formation and
neurofibrillary tangles. We now refer to these disorders as the British
and Danish forms of familial bri dementia.
51 NON-CONVULSIVE STATUS EPILEPTICUS: A PROFILE OF
PATIENTS DIAGNOSED WITHIN A TERTIARY REFERRAL
CENTRE
Haffey S, McKernan A, Pang KA Royal Victoria Hospital, Belfast, Northern
Ireland, UK
Fifty episodes of NCSE were diagnosed in 45 patients over a 3 year
period. We reviewed each case for a history of GTCS prior to confir-
mation of NCSE, a previous diagnosis of epilepsy, the underlying
cause and co-morbidity along with conscious level and radiological
findings.
Of the 45 initial presentations, NCSE was suspected by the
referring clinicians in 36 cases. 25 patients had a previous diagnosis
of epilepsy, but less than half the patients were recorded as having
had a preceding GTCS.
Eleven patients had a history of learning disabilities and out of the
25 patients with previously diagnosed epilepsy, nine were thought to
be in NCSE at the time of an acute systemic infection.
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Although one third of the patients in our group were semi or uncon-
scious, 15% were alert and able to cooperate with the EEG.
We concluded that NCSE can occur in patients with no known his-
tory of epilepsy and should be considered as a differential diagnosis
in prolonged postictal status.
Clinicians should maintain a high index of suspicion even in
patients who appear to be alert and cooperative.
52 TILT TABLE TESTING REFERRALS FROM AN EPILEPSY
CLINIC
Razvi SSM, Pascual J, Smith PEM University Hospital of Wales, Cardiff,
Wales, UK
Head-up tilt table testing (TTT) is commonly used to investigate undiag-
nosed blackouts. Over 36 months, 132 patients referred from the epi-
lepsy clinic underwent TTT. The main indication was recurrent
undiagnosed blackouts likely to be vasovagal syncope. We did not
refer clinically definite vasovagal syncope. TTT involved passive
upright tilt at 60 degrees for 45 minutes. Complete data were
available on 128 patients (51 male) aged 14–80 (mean 37.1) years.
Three diagnostic groups were identified before knowledge of the TTT
results.
Probable vasovagal syncope (n=75). TTT was positive in 49 (65%),
but subsequent diagnostic changes were rare, even with a negative
test (n=4 (5%), 1 with epilepsy, 3 with other disorders).
Possible vasovagal syncope (n=34). TTT was positive in 16 (47%)
and the diagnosis subsequently changed in 12 (35%) (6 epilepsy, 6
other disorders).
Epilepsy with possible vasovagal syncope (n=19). TTT was positive
in 6 (32%) and prompted diagnostic change in 11 (58%) (epilepsy
excluded in two, syncope unlikely in 9).
Twenty seven of 45 patients (60%) previously treated with antiepi-
leptic drugs were considered not to have had epilepsy.
We conclude that TTT is useful in investigating undiagnosed black-
outs, particularly for possible rather than probable vasovagal
syncope.
53 DELAYS IN THE DIAGNOSIS OF PSYCHOGENIC
NON-EPILEPTIC SEIZURES
Reuber M, Fernandez G, Bauer J, Helmstaedter C, Elger CE University of
Bonn, Germany
Purpose: The prevalence of psychogenic non-epileptic seizures
(PNES) in the community has been estimated as 4% that of epilepsy.
PNES mainly affect young adults. Whilst overall outcome in terms of
independent living is poor, several studies have shown that it is better
if the diagnosis is made early. Our study describes the time to diagno-
sis in 313 consecutive patients and analyses factors contributing to
delay.
Methods: All patients in whom a diagnosis of PNES was
established at the Department of Epileptology, Bonn, Germany,
between 1991 and 2001 were considered for inclusion (n=337).
Time of manifestation, clinical details and results of investigations
were retrieved from the records. Patients were excluded if the manifes-
tation was not recorded (n=24). Mean delays were compared using t
tests for independent samples. The relationship between continuous
variables and diagnostic delay was examined using a Pearson corre-
lation.
Results: PNES were diagnosed after a mean of 7.2 years (SD 9.3
years). Younger age, interictal epileptiform potentials anticonvulsant
treatment were associated with longer delays. Other patient factors
did not explain diagnostic delay.
Conclusion: Mean diagnostic delay of PNES was over 7 years.
Patient factors did not explain the great variability of delay suggesting
that physician factors played an important role.
54 QUANTITATIVE T2 MAPPING DEMONSTRATES
ABNORMALITIES IN LOCALISATION-RELATED EPILEPSY
Rugg-Gunn FJ, Symms MR, Boulby PA, Barker GJ, Duncan JS Institute of
Neurology, London, UK
Background: Quantitative T2 mapping has previously been used in
the evaluation of the hippocampus in patients with temporal lobe epi-
lepsy, and has been shown to confer additional sensitivity over quali-
tative assessment. The aim of our study was to test the hypothesis that
T2 mapping of the whole brain would identify regions of abnormality
in patients with localisation related epilepsy.
Methods: We acquired whole brain dual echo fast FLAIR MR
images from 30 healthy subjects, nine patients with acquired lesions,
14 patients with malformations of cortical development (MCD), and
30 patients with refractory partial seizures and normal conventional
MRI. The T2 maps of each patient were compared on a voxel by voxel
basis to the control group using SPM99.
Results: Significant increases in T2 signal were identified in all
patients with acquired lesions, and in 12 patients with MCD. Abnor-
malities were also found in 12 of the 30 MRI negative patients, 10 of
which concurred with electroclinical data.
Discussion: T2 mapping was sensitive in identifying regions of
acquired injury or MCD, in some cases detecting abnormalities in
regions previously thought to be normal. The T2 abnormalities in the
MRI negative patients could be caused by either aetiological factors,
such as occult MCD or as a result of chronic seizures, for example,
atrophy and gliosis. These results show that T2 mapping, analysed on
a voxel by voxel basis, is a promising imaging method for the evalua-
tion of patients with partial seizures and normal conventional MRI.
55 A NOVEL LOCUS ON CHROMOSOME 2P 14-21 IN A
BRITISH FAMILY WITH GENERALISED EPILEPSY AND
FEBRILE SEIZURES
Siddiqui A, Johnson M, Dixon PH, Davis M, Koepp M, Shorvon SD, Sander
JWA, Gardiner RM, Duncan JS, Wood NW Institute of Neurology, London;
Royal Free and University College Medical School, London, UK
A large British family was identified with 12 affected individuals that
manifested a variety of childhood onset epilepsies. The phenotype in
this family included absences, myoclonus, frontal lobe epilepsy and
generalised epilepsy, with or without preceding febrile seizures.
Many of the individuals have features consistent with idiopathic gen-
eralised epilepsy. Linkage analysis has been performed and excluded
the known loci for Generalised Epilepsy and Febrile Seizures plus
(GEFS plus) ie, GEFS 1 and 2 (sodium channel genes SCN1B and
SCN1A on chromosome 19 and 2 respectively) and GEFS 3
(GABA(A) receptor gamma 2-subunit gene on chromosome 5). The
other subunits for the GABA(A) and GABA(B) receptors were also
excluded. A genome wide search was then performed. Linkage was
found to marker D2S337, with a maximum lod score of 3.05 at u=0.
The candidate interval was flanked by markers D2S391 and D2S296,
defining a region of 23cM. We have therefore identified a new locus
for GEFS plus on chromosome 2 at 2p 14–21. This indicates further
heterogeniety for the GEFS plus phenotype. Potential candidate genes
in this region are KCNK12, a potassium channel gene and SLC1A4,
a solute carrier involved in chloride transport.
56 PRESENCE OF ANTI-GLUR3 ANTIBODIES IN
RASMUSSEN’S ENCEPHALITIS
Watson R, Lang B, Beeson D, Bermudez I Weatherall Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford, UK
Background: Rasmussen’s encephalitis (RE), which normally presents
in children, is a rare progressive neurological disorder in which an
autoimmune aetiology has been implicated. It is characterised by
focal motor seizures evolving after a variable period of time to
produce a focal neurological deficit, namely a hemiparesis with addi-
tional sensory deficits and cognitive deterioration. Antibodies against
the AMPA-sensitive glutamate receptor 3 (GluR3) have been detected
in some RE patients. Here we investigate the prevalence of these anti-
bodies in sera from 20 RE patients.
Methods: We have cloned a full length GluR3 from human cDNA
library, subcloned into the mammalian expression vector pcDNA3.1
Hygro and expressed in HEK 293 cells through transient transfection.
Anti-GluR3 antibodies were screened using western blotting of the
HEK-GluR3 cell lysate and ELISA using GluR3 peptides. GluR3 mRNA
injected into X. Oocytes was used to investigate the electrophysiologi-
cal functionality of these antibodies.
Results: Out of 20 patients screened, one tested positive for anti-
GluR3 antibodies using western blotting. Two patients evoked unusual
currents in patch-clamping experiments that are not seen in other RE
patients or controls.
Discussion: The data suggests that in a few patients with RE,
autoantibodies may have a pathogenic role in the disease. However,
an anti-GluR3 antibody mediated aetiology for RE should not be impli-
cated until there has been a definitive screen for these antibodies.
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57 THE MOLECULAR BASIS FOR ABERRANT GENE
REGULATION IN FRIEDREICH’S ATAXIA
Everett CM, Saveliev A, Webster Z, Wood NW, Festenstein R
Hammersmith Hospital; Institute of Neurology, National Hospital for Neu-
rology and Neurosurgery, London, UK
Homozygous expansion of a GAA trinucleotide repeat within the first
intron of the frataxin gene causes Friedreich’s ataxia. The basis for
frataxin gene repression in vivo is unclear. GAA repeat expansions
may repress gene expression through an effect on DNA chromatin
packaging.
Genes placed close to tightly packaged repressive chromatin
exhibit a characteristic variegated expression profile, where a
proportion of cells that would normally express become silenced. A
human CD2 1.3 (hCD2 1.3) reporter behaves in this manner in trans-
genic mice. If an expanded GAA repeat, linked to hCD2 1.3, acts to
condense chromatin then expression of hCD2 from this transgene
would variegate even when integrated on the chromosomal long arm.
Here chromatin is usually relaxed and permissive for gene expression.
Twelve hCD2 1.3(GAA)200 transgenic mouse lines were generated.
Expression of hCD2 on T lymphocytes was measured by flow
cytometry. In lines where the transgene integrated on chromosomal
long arms, expression variegated strongly. DNase I hypersensitivity
analysis confirmed that in non expressing T lymphocytes, hCD2 1.3
regulatory sequences were converted to tightly condensed chromatin.
Therefore a novel mechanism of GAA repeat mediated gene silenc-
ing occuring at the chromatin level was identified. Understanding such
molecular mechanisms may provide future therapeutic strategies.
58 CLINICAL AND GENETIC CHARACTERISATION OF
FAMILIES WITH TRIPLE A (ALLGROVE) SYNDROME
Houlden H, Smith S, de Carvalho M, Mathias C, Blake J, Wood NW, Reilly
M Institute of Neurology, London, UK
Triple A (Allgrove) syndrome is characterised by achalasia, alacrima,
adrenal abnormalities and a progressive neurological syndrome.
Affected individuals clinically have between two and four of these
relatively common problems; hence the diagnosis is often difficult in all
but the classical presentation. The inheritance is autosomal recessive
and most cases of triple A have no family history. The triple A gene
was recently identified at this locus and mutations reported in families
from North Africa and Europe. The majority of mutations were homo-
zygous.
We have identified 20 families with the clinical features associated
with the triple A syndrome. Sequencing of the triple A gene revealed
five families had a total of nine compound heterozygous mutations
and one family had two homozygous mutations; these changes were
spread throughout the triple A gene in exons 1, 2, 7, 8, 10, 11, 12,
13, 16 and the poly A tract. Families were clinically characterised in
detail. Those bearing mutations had the classical triple A syndrome of
achalasia, alacrima, adrenal abnormalities and a progressive neuro-
logical syndrome. We identified a spectrum of associated neurologi-
cal abnormalities in these cases, including pupil abnormalities, optic
atrophy, autonomic neuropathy and distal motor neuropathy with
severe bilateral ulnar nerve involvement. In these families we have
made genotype-phenotype correlations.
59 GIANT AXONAL NEUROPATHY IS CAUSED BY
MUTATIONS IN THE GIGAXONIN GENE: CLINICAL,
GENETIC, AND PATHOLOGICAL CHARACTERISATION
OF THREE FAMILIES
Houlden H, Roper H, Willis T, Schenone A, Di Battista C, Wood NW,
Reilly M Institute of Neurology, London, UK
Giant axonal neuropathy (GAN) is a severe childhood onset
autosomal recessive sensorimotor neuropathy affecting both the
peripheral nerves and the central nervous system. Ultrastructurally,
axons are distended by masses of tightly woven neurofilaments. Kera-
tin intermediate filaments also seem to be altered as most patients
present characteristic curly or kinky hair. Recently the Gigaxonin gene
on chromosome 16q24 was identified as the cause of GAN.
We sequenced all 11 exons and flanking intronic sequences of the
Gigaxonin gene in three families with childhood onset neuropathy,
typical sural nerve biopsy appearance and tight curly hair. We iden-
tified novel mutations in the Gigaxonin gene in all three families. Two
consanguineous Pakistani families from Birmingham had homozygous
mutations. The first family with one affected individual had a non-sense
mutation in exon 10. The second Pakistani family had two affected
individuals with homozygous missense mutations in exon 1. The third
family was from Italy and had compound heterozygous mutations in
the Gigaxonin gene that both caused amino acid changes. All muta-
tions were not present in controls. We are currently sequencing the
Gigaxonin gene in other individuals and we are offering this on a
research basis in potential cases.
60 A PARADIGM FOR EXPLORING THE GENETIC CONTROL
OF BRAIN DEVELOPMENT AND FUNCTION
Mitchell TN, Free SL, Shorvon SD, Sisodiya SM Institute of Neurology, Lon-
don, UK
Background: Identification of the genes involved in the control of
human cerebral development is important in the investigation of neu-
rodevelopmental disorders, such as epilepsy and learning disability.
We present an MRI paradigm to examine the effects of one such
gene, PAX6. Absence of functional PAX6 protein causes lethal
cerebral malformations. Murine models suggest heterozygous PAX6
loss of function mutations (haploinsufficiency) causes subtle malforma-
tions. The biological effect and severity of PAX6 mutations differ, with
haploinsufficiency being most severe. Human PAX6 heterozygotes
have aniridia, but the cerebral effects are yet undetermined. MRI can
reveal subtle cerebral malformations, with quantitative analysis
extracting further structural information not evident on visual
inspection.
Methods: We performed qualitative and quantitative MRI analysis
in 20 patients with PAX6 mutations (point mutation, C-terminal expan-
sion, missense mutation) and 100 sex/age-matched controls.
Results: Nine of 13 with point mutations had an absent anterior
commissure and intact corpus callosum (a novel malformation). The
anterior commissure was present in all patients with other mutations in
addition to the 100 controls. Twelve of 13 had hyposmia.
Quantitative analyses of cerebral morphology and connectivity
(callosal cross sectional area, white matter surface area) were also
abnormal.
Discussion: Using MRI we demonstrated differential effects of dif-
ferent PAX6 mutations. Consequences of PAX6 haploinsufficiency may
include disruption of cellular differentiation, neuronal migration and
axon guidance, functions known from murine models to be influenced
by PAX6. Our study shows PAX6 is a candidate gene for human cer-
ebral, as well as ocular, maldevelopment and that MRI provides a
method for examining neurodevelopmental regulators.
61 BRAIN STEM DYSFUNCTION SPECIFIC TO MIGRAINE
HEADACHE
Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ Institute of
Neurology, London, UK
Introduction: Primary headache syndromes have been classically
diagnosed and differentiated by a sound history. Positron emission
tomography (PET) studies have shown a differential brain activation
pattern in migraine and cluster headache, specifically, brainstem acti-
vation during migraine and hypothalamic activation during cluster
headache. We report two single PET studies in patients with both
migraine and cluster headache who experienced a migraine attack
while in an active cluster period.
Methods: The patients were imaged with PET following nitroglyc-
erine provocation. An H215O bolus technique was used to examine
changes in regional cerebral blood flow, as an index of synaptic
activity. The data were analysed using Statistical Parametric Mapping
‘99.
Results: Both patients experienced a typical migraine headache
fulfilling International Headache Society criteria despite being in an
active cluster period. First, there was activation of structures generally
reported in functional brain imaging studies of pain : the cingulate,
prefrontal, posterior insular and cerebellar cortices, the thalamus and
basal ganglia. Secondly, there was strong bilateral activation
corresponding to the region of the large intracranial vessels, which
resolved with treatment of the headache. Thirdly, there was lateralised
activation of the rostral brainstem which persisted following treatment
with sumatriptan, and headache resolution. There was no activation of
the hypothalamus.
Conclusion: These data demonstrate attack phenomenology
predicting the appropriate brain activation pattern and the fundamen-
tally neurovascular nature of migraine headache.
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62 A GENOME-WIDE SCAN OF 42 CANADIAN FAMILIES
SUFFERING MIGRAINE WITH AURA
Cader MZ, Noble-Topham SE, Mandalfino P, Wingerchuk D, Brown JD,
Rice GPA, Weber JL, Ebers GC Radcliffe Infirmary, Oxford, UK
Background: Migraine is a common neurological condition affecting
upto 18% of the population. Classic migraine is associated with an
aura (MA) and epidemiological studies suggest a strong genetic com-
ponent. Linkage analysis can be useful in identifying susceptibility loci
in complex traits and we have performed a genome wide scan to
identify any such loci in 42 Canadian families
Methods: Forty two families with MA were interviewed using a
validated migraine questionnaire. Headache type was classified using
the International Headache Society (IHS) criteria. A genome wide
scan was performed using 366 autosomal microsatellite markers and
the Marshfield Genotyping Service. Fastlink 5.01 was used for 2 point
linkage analysis.
Results: We did not find any regions of significant linkage in the
total population. Two loci on chromosomes 1 and 11 were suggestive
of linkage and had LOD scores greater than 2.0. However some indi-
vidual families gave scores above 2.
Discussion: Linkage has recently been reported on 55 Finnish
families to chromosome 4 with a 2 point Lod score of 3.75. In our
study there was no evidence of linkage in this region. This supports
MA being a heterogeneous disorder. Further analyses with a larger
number of families may help elucidate the susceptibility loci.
63 PROLACTINOMA AND DOPAMINE-AGONIST INDUCED
HEADACHE
Levy M, Matharu MS, Goadsby P Institute of Neurology, London, UK
Introduction: Headache is a common problem in patients with pitui-
tary tumours. Small pituitary lesions can cause debilitating headache,
and suggest that the size of the pituitary tumour may not be the only
causal factor in pituitary-related headache. Dopamine has been pro-
posed to be an important neurotransmitter in primary headaches, and
report two cases of primary headache triggered by dopamine
agonists. We describe the clinical course of two patients with pituitary
tumours experiencing distinct headaches that were exacerbated by
dopamine agonists.
Case 1: A 36 year old woman, with no headache history,
presented in 1987 with secondary amenorrhoea, galactorrhoea and
headache. Serum prolactin was 700 (27–525) mU/l and MRI
confirmed a microprolactinoma. The headache was described as a
constant left-sided sharp ‘knife-like’ pain with during exacerbations.
An exacerbation would typically last between 10 seconds and 4 min-
utes and would occur up to 20 times a day. Precipitants for exacerba-
tions included bending, walking and moving about. In between these
exacerbations, she had a continuous dull left sided pain. During an
exacerbation, she experienced ipsilateral cranial autonomic symp-
toms of lacrimation, nasal stuffiness, and ptosis. The clinical diagnosis
of short lasting unilateral headache attacks with conjunctival injection
and tearing (SUNCT) was made. The headaches completely settled
after pituitary surgery and returned when the tumour recurred.
Treatment with cabergoline and quinagolide on separate occasions
triggered prolonged and very severe episodes of pain.
Case 2: A 40 year old woman presented in 1997 with right sided
throbbing headaches. She had experienced headaches during her
menarche and has a sister with migraine. She had not experienced
headache for over 20 years. The presenting headache was
associated with nausea, vomiting, photophobia, and phonophobia.
Movement would exacerbate the headache. A typical attack would
last 3–4 days, and occurred every 2 weeks. During an attack, she
experienced ipsilateral conjunctival injection and lacrimation. Concur-
rently, she developed secondary amenorrhoea; serum prolactin was
2300 mU/l amd MRI showed a microprolactinoma. On treatment with
bromocriptine she developed daily headache that persisted after ces-
sation of treatment. Eventually she responded to treatment with
indomethacin. The second case has a clinical diagnosis of hemicrania
continua.
Conclusion: In each case, the administration of dopamine
agonists led to an exacerbation in symptoms. This suggests that the
dopamine-prolactin axis may be important in understanding the
pathophysiology of primary headache syndromes.
64 GREY MATTER NEURONAL LOSS IN MULTIPLE
SCLEROSIS
Cifelli A, Wylezinska M, Esiri M, Palace J, Matthews P The Radcliffe Infir-
mary, Oxford; FMRIB Centre, Oxford, UK
Multiple sclerosis (MS) is viewed as a prototype of white matter
disease. Axonal loss has been increasingly recognised as an
important contributor to disability. We have investigated the
involvement of grey matter and neurons in MS.
Thalamic: (a) volume with magnetic resonance imaging (MRI), (b)
neuronal integrity with proton magnetic resonance spectroscopy
(MRS), (c) neuronal numbers with histopathology techniques were
assessed. Fourteen secondary progressive patients and 14 age
matched healthy controls were studied with 1H-MRS and MRI. Neuro-
nal numbers in the thalamic mediodorsal (MD) nucleus were obtained
in postmortem specimens from 10 MS cases and 10 non-neurological
controls using histopathological techniques.
Thalamic: (a) volumes, (b) NAA concentrations (a) neuronal
marker, and (c) total neuronal numbers, were all significantly lower in
MS patients compared with controls.
Such neuronal loss in the grey matter could play a major role in the
permanent disability and cognitive dysfunction of MS which have so
far been attributed to white matter damage.
65 TRIPLE DOSE GADOLINIUM ENHANCED MRI OF THE
BRAIN AND SPINAL CORD IN EARLY RELAPSING
REMITTING MULTIPLE SCLEROSIS IS PREDICTIVE OF
FUTURE RELAPSES
Davies GR, Chard DT, Griffin CMB, Rashid W, Thompson AJ, Miller DH
Institute of Neurology, London, UK
Background: Triple dose gadolinium (Gd) enhanced MRI is more
sensitive at detecting active multiple sclerosis lesions than MRI with
standard dose (0.1mmol/kg) enhancement. This study has assessed
the ability of triple dose gadolinium enhanced MRI to predict
subsequent relapse rate in a cohort of early relapsing-remitting multi-
ple sclerosis (MS) subjects.
Methods: Thirteen subjects with symptoms of MS for less than 3
years were imaged at months 0, 1, 2, and 3 with triple dose Gd
enhanced MRI of the brain and spinal cord. Lesions that were identi-
fied as newly enhancing after baseline were used to calculate the
mean enhancing lesion number for the three month period. Relapse
rate was assessed every 6 months for 2 years.
Results: Mean enhancing lesion number for the first 3 months
(cord and brain combined) correlated significantly (Spearman’s coef-
ficient rs=0.77, p=0.002) with yearly relapse rate for the whole 24
month period.
Discussion: Given the strong correlation seen between enhancing
lesion number and relapse rate it is likely that triple dose Gd enhanced
imaging of the brain and spinal cord provides a better assessment of
inflammatory disease activity than single dose Gd enhanced brain
imaging alone. The homogeneous nature of the cohort could also have
improved the correlation.
66 A GENOME-WIDE SCAN FOR REGIONS SHARED
IDENTICAL BY DESCENT IN HUTTERITE MS FAMILIES
Dyment DA, Datta A, Steckley JL, Willer CJ, Sadovnick AD, Risch NJ,
Hader W, Ebers GC University of Oxford; University of Saskatoon;
Stanford University, USA; University of British Columbia, Canada
Background: The Hutterites are a religious group living throughout
mid-western Canada and the United States. They have practiced a
degree of endogamy for the last 100 years and as a result an
individual Hutterite is related to another as a first cousin once
removed. They have been a useful study group for the study of infertil-
ity and asthma.
The complexity of MS genetics has made the search for novel genes
using sib-pair allele sharing methods difficult. To minimise the genetic
heterogeneity thought to be present in the MS population, we
screened the Canadian MS population for people belonging to the
Hutterite Brethren.
Methods: In a screen of 18 000 Canadian MS patients the
CCPGSMS identified seven individual Hutterites with clinically definite
multiple sclerosis. These seven MS patients are all related to a
common founder couple by eight generations. We genotyped these
seven people and their 22 family members for 400 markers.
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Haplotypes were then created and visually inspected to see which
intervals were shared among the MS patients.
Results: There was no interval shared among six MS patients (one
patient of the seven refused to have familiy members contacted). How-
ever there were five regions (6p21, 6q, 14q, 15p, 17p, 18q) that
were shared among five of the six Hutterites MS patients. The HLA
Class II region was one of these five shared regions. The haplotype
shared did not bear the DRB1*15 allele but the DRB1*04 allele.
Discussion: No single region was shared between the Hutterite
patients. This could be due to the resolution of the markers used or
heterogeneity in MS pathogenesis in this Founder population. This
strategy does work as the MHC was identified in the screen. Interest-
ingly, the MS associated MHC haplotype in this population was not
the DRB1*15 allele but DRB1*04, allele suggesting a situation
perhaps more akin to that seen in Sardinia.
67 CHARACTERISATION OF THE ASTROCYTIC GLIAL SCAR
IN MULTIPLE SCLEROSIS
Gutowski NJ, Holley JE, Gveric D, Newcombe J Royal Devon and Exeter
Hospital, Exeter; Institute of Neurology, London, UK
Introduction: In the chronic plaques of multiple sclerosis (MS), astro-
cytic scarring inhibits tissue repair. Animal work has shown that the
antigenic phenotype of the most abundant cell type in the brain, the
astrocyte, varies depending on astrocyte type and location.
Characterisation of human astrocytes in MS tissue may identify mark-
ers of the scarring seen in chronic lesions.
Methods: Astrocytic phenotype was investigated in sub-ventricular
white matter by immunocytochemistry and western blotting. Snap fro-
zen tissue from normal controls (n=4), MS normal appearing white
matter (n=5) and lesions [acute (n=7), sub-acute (n=7) and chronic
(n=13)] was studied.
Results: As expected, glial fibrillary acidic protein, vimentin and
tenascin-C and -R expression was elevated in areas of scarring. There
was also increased expression of nestin, embryonic neural cell adhe-
sion molecule, receptor nerve growth factor, nerve growth factor, and
its receptor p75.
Conclusion: Changes in expression of several proteins have been
found to characterise the scar astrocyte phenotype in chronic MS
lesions. The role of proteins associated with development, growth fac-
tors and growth factor receptors in glial scar formation and tissue
repair is the subject of further investigation.
68 EVALUATING THE USE OF Β-INTERFERON IN THE UK:
FROM WHOSE PERSPECTIVE?
Hobart J, Riazi A, Lamping D, Fitzpatrick R, Thompson AJ Institute of Neu-
rology, London; Derriford Hospital, Plymouth, Devon, UK
The Department of Health have announced they intend to fund a
scheme making β-interferon available for people with MS in the UK.
Longitudinal data will be collected to evaluate change over time. We
examined how the choice of rating scale could influence the results of
that scheme.
Three groups of people with MS were studied: consecutive admis-
sions for inpatient rehabilitation (n=64) and IV steroids for relapses
(n=77), a cohort with primary progressive MS (n=104). Multiple rat-
ing scales were administered to all samples at two points in time.
Scales were physician-based (eg. Expanded Disability Status
Scale-EDSS, MS Functional Composite-MSFC, Guys Neurological Dis-
ability Scale-GNDS) and patient-based (eg, Multiple Sclerosis Impact
Scale-MSIS-29, Short Form 36-SF36).
We examined the reliability and validity of each scale, correlations
between physician and patient-based scales purporting to measure
similar aspects of health, the ability of competing scales to detect
change, the interpretation of change scores.
All scales satisfied standard reliability and validity criteria. Correla-
tions between physician and patient-based scales varied (0.20 to
0.75). The ability of competing scales to detect change varied (effect
size 0.10 to 1.0). The “effectiveness” of rehabilitation and steroids, as
judged by statistical significance of change scores, was scale depend-
ent. Significant changes were demonstrated with some patient-based
scales (eg. MSIS-29, SF-36) but not some physician-based scales
(EDSS, MSFC).
The outcome of the scheme will almost certainly be influenced by
the choice of rating scale and the perspective of the rater.
69 SERUM AUTOANTIBODIES AGAINST INTRACELLULAR
ANTIGENS IN MULTIPLE SCLEROSIS
Lily O, Palace J, Vincent A Radcliffe Infirmary, Oxford, UK
Multiple sclerosis (MS) is thought to be an organ-specific autoimmune
disease. The hallmark of these disorders is the production of autoanti-
bodies. In many cases, autoantibodies are directed against intracellu-
lar antigens. A number of intracellular antigens have been proposed
for MS, including the heat-shock protein, alpha-B crystallin.
We tried to demonstrate autoantibody binding to intracellular anti-
gens using sera from MS patients. Immunohistochemistry with rat brain
stem tissue sections failed to show significant antibody binding in any
of 40 MS patients. Flow cytometry of permeabilised human
oligodendrocyte, astrocyte and neuronal cell lines failed to show any
significant difference in antibody binding between 58 MS patients
and 28 controls. When the oligodendrocyte cell line was pretreated
with heat shock, there followed a marked increase in antibody bind-
ing from MS sera. However, this was also seen with control sera. Heat
shock had no effect on antibody binding to the astrocyte cell line.
We conclude that there is no evidence for autoantibodies against
intracellular antigens in MS patients. Autoimmunity toward heat shock
proteins may be a feature of inflammation and may account for the
relative vulnerability of oligodendrocytes to inflammatory damage. If a
specific autoimmune process underlies MS, then the autoantigen is
likely to be a cell surface protein.
70 MULTIPLE SCLEROSIS IN SOUTHEAST IRELAND:
UPDATING THE PREVALENCE
McGuigan C, McCarthy A, Hawkins S, Hutchinson M St Vincents Univer-
sity Hospital, Dublin, Ireland
Objective: To determine the prevalence of, and range of disability
due to, multiple sclerosis (MS) in County Wexford in the Republic of
Ireland.
Background: The south east of Ireland has been considered to
have a relatively low prevalence of MS. Previous prevalence data has
been published on County Wexford; Brady et al in 1971: 54.5 per
100 000 and Hutchinson in 1984: 48.4 per 100 000.
Methods: Sources of case ascertainment were: a postal survey of
general practitioners, county physicians and consultant neurologists;
hospital coding lists; the local MS society; respite care facilities and
interferon prescription lists.
Results: One hundred and twenty six patients with clinically
definite or probable MS (Poser criteria) were identified from 161
referrals, a prevalence rate of 120.7 per 100 000 (95% confidence
intervals 99.6–141.8 per 100,000). Approximately 70% of these
patients were individually assessed. The age range of prevalent cases
is 19 to 73 years, mean age 47.5 years, and mean age at onset 35.6
years. Female to male ratio 2.2:1. Mean Kurtzke expanded disability
score 4.36 (0–9.5); Multiple sclerosis functional composite score
21.281 (26.5535–0.7739); and multiple sclerosis physical impact
scale score 37.54 (0–85).
Conclusions: County Wexford has a higher prevalence of MS
than previously reported. This is unlikely to represent a true increase in
prevalence but better case ascertainment, earlier diagnosis and
increased survival.
71 NO EVIDENCE TO SUPPORT CTLA4 AS A MULTIPLE
SCLEROSIS SUSCEPTIBILITY GENE
Morrison K, Dyment DA, Willer CJ, Risch N, Sadovnick AD, Ebers GC Uni-
versity of Oxford, UK; University of Stanford, USA; University of British
Columbia, Canada
Background: The cytotoxic T lymphocyte antigen 4 gene (CTLA-4) is
involved in the regulation of T cell proliferation. During T cell
activation, CTLA-4 is expressed on the surface of the T cell. It then
binds to its B7 ligand on the antigen presenting cell (APC) and signals
an end to the T cell proliferation response. As such, CTLA-4 serves as
a candidate susceptibility gene for autoimmune disorders. Polymor-
phisms at the CTLA-4 locus have been shown to be associated with
autoimmune disease such as Hashimotos thyroiditis, diabetes, Graves
disease, and multiple sclerosis.
Methods: Two polymorphisms of the CTLA-4 gene were geno-
typed in 232 sibling pairs affected with multiple sclerosis (MS) from
185 families. The CTLA-4 polymorphisms genotyped were an 39
untranslated (AT) n microsatellite and an alanine/threonine RFLP of
exon 1.
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Results: There was no evidence for linkage by either identify by
descent or identify by state methods. A transmission disequilibrium test
(TDT) was performed and no preferential transmission of alleles was
observed. Upon stratification of patients, there was observed no pref-
erential transmission based upon gender, by presence or absence of
HLA*DRB1*15 by ethnicity or by clinical course of the disease.
Discussion: CTLA-4 does not appear to be a major MS
susceptibility locus in Canadian multiplex families.
72 THE UK MS DATABASE
Palace J, Hoddell B, Boggild M, Rogers S The Radcliffe Infirmary, Oxford;
The Walton Centre, Liverpool, UK
The UK has a high incidence of multiple sclerosis (MS) with an
estimated 85 000 cases, however, the number of neurologists—and
specifically neurologists with an interest in MS—remains low by com-
parison to North American and northern European figures. Though the
few expert clinicians in this field poses obvious difficulties, services for
patients with MS have expanded in recent years—hand in hand with
developments in disease modifying therapies. MS services are
provided in different settings, ranging from academic centres with
multidisciplinary teams to single handed neurologists within district
general hospitals. Though a number of centres have basic, locally
developed database systems, no common system for data collection is
available, nor have more than a handful of centres become involved
with the EDMUS database system.
The UK MS database represents an attempt to develop a bespoke
but flexible MS database system to meet the varied needs of clinicians
working with MS patients in the UK. The system was developed
following consultation with representatives from more than 20 centres
across the UK, with input from professionals across a range of
disciplines, involved in the care of patients with MS. As a result of this
combination, the database has been designed as a free standing sys-
tem for local use on laptop or network systems.
The key features of the system are as follows:
Microsoft Access based system;
Minimal core data set;
Additional data modules which can be configured locally;
Multidisciplinary input;
Graphical displays of individual patient histories;
Flexible data analysis package;
Potential for data pooling via SQL server system.
Database coordinators have been employed to support the
package within centres across the UK and the system will be subject to
regular updates through a central user group. The database has com-
pleted final pilot testing in a variety of settings across the UK and is
now freely available. The database will be demonstrated with the
poster.
73 THE COMPARATIVE INVESTIGATION OF CEREBRAL
PERFUSION IN MULTIPLE SCLEROSIS USING A NOVEL
TECHNIQUE
Rashid W, Parkes LM, Ingle GT, Chard DT, Tofts PS, Miller DH Institute of
Neurology, London, UK
Background: Cerebral perfusion in multiple sclerosis (MS) has not
been previously estimated using continuous arterial spin labelling
(CASL), an MRI technique using endogenously labelled arterial water.
This is potentially more accurate than other techniques as it allows
quantitative perfusion estimates with less susceptibility to contrast loss
in areas of blood brain barrier disruption. This study compares
perfusion measures between normal controls and subtypes of MS
using CASL.
Methods: Thirty two normal controls and 34 MS subjects (11 pri-
mary progressive, 10 relapsing remitting (RR), eight benign, five sec-
ondary progressive (SP)) were compared using CASL.
Results: General linear modelling with age as a covariate and sex
as a fixed factor, showed a significant increase in white matter
perfusion in the RR (p=0.008) and SP (p=0.026) groups. No
significant changes were seen in the grey matter.
Discussion: Due to the small cohort sizes interpretation should be
cautious, however this is the first study to show increased perfusion in
white matter in RR and SP MS subjects. This may reflect increased
inflammatory activity in these subgroups. This study suggests CASL
may be of use in monitoring inflammatory activity in MS.
74 AUDIT OF Β-INTERFERON TREATMENT: EXPERIENCE IN
THE FIRST 100 PATIENTS WITHIN THE WALTON CENTRE
MS SERVICE
Rog DJ, Young CA, Boggild MD Walton Centre for Neurology and Neuro-
surgery, Liverpool, UK
Aim—To ascertain whether patient selection for β-interferon (β-IFN)
side-effect profile and relapse outcome in early clinical practice is in
accord with data from published randomised clinical trials (RCTs) in
relapsing remitting MS (RRMS).
Methods: We performed a retrospective case notes audit of the
first 100 patients in the Liverpool and Chester MS clinics treated with
β-IFN. Pretreatment demographic details, MS history and Expanded
Disability Status Scale (EDSS) were collected. β-INF preparation first
prescribed, number of relapses, EDSS, adverse events on treatment,
reason for withdrawal of β-IFN and subsequent alternative treatments
were determined.
Results: Eighty one patients were female. Pretreatment variables
were: 35 years (range 18–58, SD 8.06), duration of MS 7.7 years
(0.7–29, 6.39), relapses in 2 years prior to treatment 3.1 (1–7, 1.08)
and EDSS 4.4 (1.5–6.5, 1.3). Fifty patients received Rebif, 32
Avonex, and 18 Betaferon. Fifty eight patients remain on treatment
(mean 36 months), 53 are “responders” (relapse free or EDSS stable),
for all patients annualised relapse rates on treatment were reduced by
33%. For the group of patients on treatment for at least 6 months, ie
excluding early treatment failures (n=85) reduction in relapse rate was
49%. In those patients on treatment for a minimum of 12 months (74),
the reduction was 61%. Thirty one patients withdrew from treatment
(mean 15.5 months) due to disease progression or relapses. Eleven
withdrew due to adverse events (mean 5.9 months). Twenty four of
those withdrawn from β-INF are receiving alternative disease modify-
ing treatments.
Conclusions: Patients being identified for β-INF treatment broadly
match those recruited into RCTs. Adverse events also mirror those from
trials with an 11% drop out rate. The reduction in annualised relapse
rate with time on treatment reflects selection of β-IFN “responders” and
underlines the importance of operating treatment withdrawal
guidelines.
75 OVEREXPRESSION OF CD5 ON B LYMPHOCYTES
CORRELATES WITH THE DISEASE ACTIVITY IN PATIENTS
WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
Seidi OA, Semra YK, Sharief MK GKT School of Medicine; Guy’s Hospi-
tal, London, UK
Multiple sclerosis (MS) is regarded as a T lymphocyte mediated
disease. There is emerging evidence that B lymphocytes also play a
role in disease pathogenesis. A subtype of B lymphocytes, the CD5
expressing B cells, are often increased in several autoimmune
disorders. Therefore, we sought to examine the role of these cells in
MS. Using flow cytometry, we studied the expression of CD5 on per-
ipheral B lymphocytes from 28 patients with relapsing remitting MS
(RRMS), 13 of whom had active MS according to clinical and MRI cri-
teria. We also included 42 patients with other inflammatory and non-
inflammatory neurological disorders as controls. T cell expression of
CD4 and CD8 was studied for comparison. We detected significantly
high expression of CD5 on B lymphocytes from patients with active
RRMS, but in only three controls with untreated cerebral lupus. There
was no difference in the expression of the pan-B cell antigen CD19, or
T cell antigens CD3, CD4 and CD8. Within the active RRMS group,
there were no correlation between CD5 and CD19, CD3, CD4 or
CD8 expression. Our results suggest a possible pathogenic role for
CD5 in active RRMS. Further studies to explore mechanisms of traffick-
ing of these cells into the central nervous system might open avenues
for a more targeted therapy of MS.
76 FORTY MULTIPLEX FAMILIES WITH MS: LINKAGE
ANALYSIS OF CHROMOSOME 6 AND HLA-DRB1
Willer CJ, Dyment DA, Armstrong H, Risch N, AD Sadovnick, Ebers GC
Univeristy of Oxford, UK; University of British Columbia, Canada; Univer-
sity of Western Ontario, Canada; Stanford University, USA
Background: Multiple sclerosis is a neurological, autoimmune
disease that affects tens of thousands of Canadians. Family studies of
half-siblings, adoptees, and siblings have shown that susceptibility is
clearly determined by both genes and environment.
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Methods: We ascertained 18 000 Canadian patients with
multiple sclerosis and selected the 40 families that were most informa-
tive for linkage analysis. Epidemiological and clinical data was avail-
able from 187 of 252 affected individuals. Microsatellites on
chromosome 6 and the HLA-DRB1 locus were genotyped and linkage
analysis was performed.
Results: Two point parametric, multipoint parametric and NPL
analyses were performed There was suggestive but not significant link-
age to the HLA-DRB1 locus. No linkage to microsatellites in the 6p21
region was found. The results suggest there may be populations of
families in which the DRB1 has little or no influence on susceptibility
and others where it is important.
Discussion: Multiplex families have the potential to be more pow-
erful and require smaller genotyping effort. However, linkage analysis
methods are susceptible to misspecification of the inheritance patterns.
Heterogeneity is an important consideration in linkage studies of large
families of MS and its elucidation may require both genetic and epi-
demiological subgrouping.
77 RECESSIVE INHERITANCE AND VARIABLE PENTRANCE
OF SLOW CHANNEL MYASTHENIC SYNDROMES
Beeson D, Croxen R, Hatton C, Shelley C, Colquhoun D, Chauplannaz G,
Oosterhuis H, Newsom-Davis J, Vincent A University of Oxford; University
College, London, UK
Background: Reported cases of slow channel congenital myasthenic
syndrome (SCCMS) have been dominantly inherited disorders due to
missense mutations in the muscle acetylcholine receptor (AChR).
Single channel recordings show that all cause the prolonged
activations of the AChR ion channel that underlies the disease patho-
logy.
Methods: Three SCCMS families were screened for AChR
mutations using single channel conformation polymorphism analysis,
DNA sequencing and restriction endonuclease digestions. Functional
effects of the mutations were analysed using single-channel recordings
of mutant AChR expressed in HEK293 cells.
Results: We identify two new mutations in the AChR e-subunit
gene, eL78P and eL221F. The mutations prolong ion channel
activations 3.7 and 2.4 fold respectively. eL78P was identified in a
family in which symptoms only presented in the index patient,
born to consanguineous parents, who is homozygous for the mutation.
eL221F shows limited penetrance in one of the two families with this
mutation.
Discussion: Differential diagnosis between SCCMS and AChR
deficiency syndrome, which shows recessive inheritance, is important
since they require contrasting treatment strategies. Here, we provide
the first defined examples of recessive inheritance and variable
penetrance for SCCMS. A diagnosis of SCCMS should not be ruled
out in suspected cases of CMS that show a recessive inheritance pat-
tern.
78 ANTIBODIES TO FETAL ANTIGENS IN MOTHERS OF
BABIES WITH ARTHROGRYPOSIS MULTIPLEX
CONGENITA (AMC) OR OTHER
NEURODEVELOPMENTAL DISORDERS
Dalton P, Clover L, Beeson D, Vincent A Weatherall Institute of Molecular
Medicine, John Radcliffe Hospital, Oxford, UK
Background: Arthrogryposis multiplex congenita (AMC) is a
non-progressive disorder in which babies are born or die in utero with
multiple fixed joint contractures. It can be caused by any condition
which leads to restriction of fetal movement. Occasionally women with
myasthenia gravis (MG) have children with AMC due to high titres of
antibodies against the fetal isoform of the acetylcholine receptor
(AChR). However, the frequency of maternal antibody-mediated AMC
is unknown.
Methods: We tested sera from more then 200 women who have
had one or more babies with AMC or who recurrent pregnancies
affected by other developmental disorders. We used in vitro
techniques (radioimmunoassay, flow cytometry, ELISA, immunohisto-
chemistry, western blotting) on rhabdomyosarcoma and neuroblas-
toma cell lines and on human fetal and newborn mouse tissues to look
for maternal antibodies.
Results: We found fetal AChR antibodies in 2%, and antibodies to
other muscle, neuronal or chondrocyte antigens in a further 12%. The
unknown antigen(s) involved are being defined by N-terminal
sequencing and screening of cDNA expression libraries.
Discussion: The results suggest that AMC and other developmen-
tal disorders can be associated with maternal antibodies against fetal
antigens; further work is needed to define the targets and demonstrate
antibody mediated pathogenicity.
79 THE SODIUM CHANNEL SYNDROMES: EXPANDING THE
PHENOTYPE ASSOCIATED WITH SCN4A MUTATIONS
Davies NP, Sutton I, Winer JB, Moorcroft P, Pall HS, Cole T, Davies MB,
Valente EM, Brancati F, Hammans SR, Hanna MG Institute of Neurology,
London, UK
Background: Paramyotonia congenita, potassium aggravated myo-
tonia and hyperkalaemic periodic paralysis (hyperPP) are allelic
disorders caused by mutations in the skeletal muscle voltage gated
sodium channel gene (SCN4A). Certain mutations within this gene are
associated with one of the three disorders but it is now emerging that
several mutations may cause an overlap syndrome (eg, paramyotonia
with hyperPP).
Methods: We identified 15 families with either paramyotonia
congenita alone or paramyotonia congenita plus hyperPP.
Detailed clinical and neurophysiological examination (including
cold immersion EMG) was performed in each case. Molecular
genetic analysis of SCN4A was performed with a combination of
restriction fragment length polymorphism analysis and direct DNA
sequencing.
Results: Ten of the 15 probands harboured a mutation in SCN4A.
We identified new phenotypes in association with three known muta-
tions. Four families with paramyotonia/hyperPP overlap harboured
the T704M (3) or M1592V(1) mutations previously associated with
isolated hyperPP. In two families with paramyotonia/hyperPP we
identified an R1448H mutation formerly associated with isolated
paramyotonia. We identified a new mutation in exon 24 in one fam-
ily (L1435P) associated with isolated paramyotonia.
Conclusion: Overlap syndromes are common in the skeletal mus-
cle sodium channel disorders. Exon 13 (T704M) and exon 24
(R1448H, M1592V) seem to be hotspots for mutations resulting in
paramyotonia/hyperPP overlap. We have identified a new mutation
in exon 24 confirming that this exon and particularly the region
encoding the voltage sensor of domain IV is a hotspot for mutations
causing paramyotonia congenita.
80 USE OF PEPTIDE: HLA CLASS II COMPLEXES TO STUDY
SPECIFIC T CELLS IN MYASTHENIA GRAVIS
Kishore U, Zhang W, Corlett L, Kelleher A, Shiono H, Willcox N Weather-
all Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
The pathogenic autoantibodies in MG depend on specific helper T
cells. They recognise acetylcholine receptor (AchR) derived peptide
epitopes when presented by HLA-class II molecules on antigen
presenting cells. These T cells appear much less heterogeneous than
the antibody producing B cells, and therefore more suitable for
specific immuno targetting.
We have recently identified two recurring AChR epitopes that are
presented by HLA DR52a (DRB3*0101) to specific T cells cloned from
several early onset MG patients (Hill et al, 1999). To assess their
potential dominance and pathogenicity rapidly in a wider range of
patients and controls, we are using soluble peptide linked DR52a
ectodomains attached to an IgG2a Fc framework. When these
IgG-like dimers are cross linked by fluorescent protein-A, the resulting
multimers bind much more avidly to our cloned T-cells’ receptors
(which have low affinities for monomeric ligands). They give low
backgrounds on control blood T cells; we are now staining blood and
thymic cells from patients.
Soluble peptide:class II complexes are versatile reagents: mono-
mers can also induce tolerance if cultured with T cells in the absence
of antigen presenting cells, by engaging the T cells’ receptors without
costimulation. We are now comparing monomers, dimers, and
multimers, aiming to generate reagents suitable.
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81 NOVEL MUTATION IN THE MUSCLE ACETYLCHOLINE
RECEPTOR A-SUBUNIT UNDERLIES A FAST CHANNEL
CONGENITAL MYASTHENIC SYNDROME
Webster R, Vincent A, Newsom-Davis J, Beeson D Weatherall Institute of
Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Background: Congenital myasthenic syndromes (CMS) are fre-
quently caused by mutations in the muscle acetylcholine receptor
(AChR). The mutations may result in reduced receptor number and/or
kinetic abnormalities that alter AChR function.
Methods: AChR subunit genes were screened for mutations using
single strand conformation polymorphism analysis, DNA sequencing
and restriction endonuclease digestion. Effects of mutations on the
function of AChR expressed in HEK293 cells were determined by cell
attached patch-clamp single channel and burst analysis.
Results: Mutational analysis identified one missense mutation,
aF256L, present in the index patient and his father. Analysis of mutant
AChR activity showed very brief burst durations typical of a “fast
channel”. The longest population of bursts for the aF256L-AChR had a
mean duration of 1.87 ± 0.49 ms compared with 3.62 ± 0.61 ms in
wild-typeAChR. In addition, the proportion of all bursts in the longest
population was greatly reduced (1.98 ± 0.8 % for aF256L vs. 28.2 ±
3.9 % for wild-type).
Discussion: Reported cases of the fast channel syndrome have
shown recessive inheritance. Since we were unable to detect a second
pathogenic mutation, and a biopsy from the patient’s father showed
evidence of dysfunction in neuromuscular transmission, this CMS phe-
notype may result from a “dominant negative” effect of the ?F256L
mutation
82 ATYPICAL MUSCLE BIOPSY FINDINGS IN A PATIENT WITH
4Q35 FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Wood-Allum C, Brennan P, Hewitt M, Lowe J, Tyfield L, Wills A University
Hospital Queen’s Medical Centre; Nottingham City Hospital; University of
Nottingham Medical School, Nottingham, UK; Southmead Hospital,
Bristol, UK
Background: Facioscapulohumeral muscular dystrophy (FSHD) is a
common, autosomal dominant myopathy. It is usually the result of
deletions at 4q35. Current diagnostic criteria for FSHD exclude
patients with atypical muscle biopsy findings. The 64 year old man
presented here had clinical features typical of FSHD and no family his-
tory. His muscle biopsy, however, had features specific to nemaline
myopathy, a largely autosomal recessive disorder, whose clinical
characteristics overlap with FSHD. When three of his children began
to develop a similar syndrome the diagnosis was reviewed and
genetic testing for FSHD was carried out. All four family members
were found to carry a 4q35 deletion. Whilst clinically atypical 4q35
carriers have been reported, this family suggests that the histopatho-
logical spectrum of FSHD also may be broader than is currently
acknowledged.
Methods: An EcoR1/Bln 1 double digest technique was used to
test for FSHD. The VNTR probe pH30 was used on a HindIII digest of
genomic DNA to establish that all three children had inherited the
same paternal chromosome 4 allele.
Results: Muscle biopsy of the index case featured eosinophilic inclu-
sions in ∼10% of muscle fibres, identified by electron microscopy as
nemaline rods and plentiful enough to strongly suggest a nemaline
myopathy. All four affected family members, however, were subse-
quently shown to have a shortened EcoR1 digestion fragment of 17kb,
confirming the presence of a 4q35 deletion and the diagnosis of FSHD.
Discussion: Patients with no family history or evidence of an auto-
somal dominant myopathy in whom an FSHD-like syndrome is
suspected should be considered for FSHD gene testing even if their
muscle biopsy suggests an alternative diagnosis. Clinicians should in
particular consider testing for FSHD in juvenile and adult onset nema-
line myopathies. As cases accumulate of 4q35 carrying exceptions to
currently accepted diagnostic criteria for FSHD, these may require
modification.
83 SODIUM CHANNEL PLASTICITY IN PAINFUL DIABETIC
NEUROPATHY
Craner MJ, Black JA, Waxman SG VA Medical Centre, Yale University,
USA
Objectives: Diabetes mellitus (DM) is now the leading cause of per-
ipheral neuropathy worldwide of which 11–25% of patients report
pain. Accumulating evidence indicates that dysregulated sodium
channel gene transcription leads to hyperexcitability of injured dorsal
root ganglion (DRG) neurons, which can contribute to neuropathic
pain. We examined sodium channel mRNA and protein expression in
DRG to gain insight into the pathophysiology of allodynia in the strep-
tozotocin model of diabetic neuropathy.
Methods: DM was induced in Sprague-Dawley rats with
streptozotocin (60mg/kg, i.p.). Allodynia was defined as a
withdrawal threshold of <4 g by Von Frey hair assessment. In situ
hybridisation and immunohistochemistry assessed levels of mRNA and
protein respectively for sodium channels rNav1.3, rNav1.6, rNav1.8
and rNav1.9.
Results: There was a significant up regulation of rNav1.3, rNav1.6
and rNav1.9 and a down regulation of rNav1.8 mRNA. Immunohisto-
chemistry demonstrated parallel changes at the protein level.
Conclusions: Sodium channel gene expression in DRG neurons is
dysregulated in an animal model of DM, and this may lead to hyper-
excitability and neuropathic pain. Through greater understanding of
the pathophysiology of neuropathic pain we can hope to identify spe-
cific therapeutic targets.
84 CHRONIC IDIOPATHIC AXONAL POLYNEUROPATHY
AND GLUCOSE TOLERANCE
Hughes RAC, Umapathi T, Carey L Guy’s, King’s and St Thomas’ School of
Medicine, London, UK
We report on 33 patients from an ongoing investigation of chronic
idiopathic axonal polyneuropathy (CIAP). In the evaluation we placed
emphasis on elucidating possible family history, neurotoxic exposure,
occult alcoholism, undiagnosed malignancy and abnormal glucose
handling.
The mean (SD) age of the patients was 66.4 (8.9) years. Three
quarters were male. The most common clinical subtype (45%) was
painful, predominantly small fiber sensory neuropathy. The other sub-
types were painless sensorimotor (21%), painful sensorimotor
neuropathy (6%) and predominantly motor neuropathy (18%). One
patient, with a painless predominantly motor sensory neuropathy, has
a similarly affected sibling.
Twenty five per cent of all CIAP and 47% of those with painful sen-
sory neuropathy had abnormal OGTT with normal glycosylated
haemoglobin. Two patients, had glucose levels diagnostic of diabetes
mellitus, four had impaired glucose tolerance and two impaired fast-
ing glycaemia as defined by WHO. All but one had painful sensory
neuropathy.
In summary CIAP is heterogeneous but the proposed clinical
subtypes delineated may define more homogeneous entities. In
support of this hypothesis, about half of CIAP patients have a painful,
predominantly small fibre sensory neuropathy in which impaired glu-
cose tolerance may be an aetiological factor.
85 THE RISK OF RELAPSE OF GUILLAIN-BARRÉ SYNDROME
OR CHRONIC INFLAMMATORY DEMYELINATING
POLYRADICULONEUROPATHY FOLLOWING
IMMUNISATION
Pritchard J, Mukherjee R, Hughes RAC Guy’s, King’s and St Thomas’
School of Medicine, London, UK
Background: The safety of immunisation after recovery from
Guillain-Barré syndrome (GBS) or in the related condition chronic
inflammatory demyelinating polyradiculoneuropathy (CIDP) is not
known. Patients and physicians often avoid immunisation for fear of
precipitating relapse.
Methods: We audited the occurrence of self reported relapse in a
postal survey of 3000 members of the GBS Support Group. We relied
upon patients’ own reports of their underlying condition and relapses,
confirming the latter by telephone discussion or by consultation with
their neurologist.
Results: After immunisation, eleven out of 311 GBS patients and
five out of 65 CIDP patients noted recurrent neurological symptoms.
None of the GBS patients were hospitalised or treated. In two of the
CIDP patients the deterioration was sufficient to cause a temporary
increase in the modified Rankin scale score from 1 to 4.
Discussion: The method of data collection may have overesti-
mated the incidence of relapse rates after immunisation. Nevertheless
we can conclude with 95% confidence that in GBS the risk of relapse
after immunisation requiring treatment or hospitalisation is less than
1.2%. In CIDP the upper 95% confidence limit of the risk of recurrent
symptoms following immunisation was 17%, which may in part reflect
the natural history of the disease.
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86 CABERGOLINE MONOTHERAPY IN CLINICAL PRACTICE:
A TWO YEAR OBSERVATIONAL STUDY OF TOLERABILITY
AND EFFICACY IN YOUNG, OLD AND VERY ELDERLY
PATIENTS WITH PARKINSON’S DISEASE
Appiah-Kubi LS, Nisbet A, Burn DJ, Ray Chaudhuri K King’s College Hos-
pital; University Hospital, Lewisham; GKT School of Medicine; Royal Sus-
sex County Hospital; Newcastle General Hospital, UK
Background: Cabergoline (CBG), the longest acting dopamine agonist,
provides physiological sustained stimulation of dopamine receptors. We
have reported efficacy of cabergoline in young and elderly Parkinson’s
disease (PD) patients, yet concerns over presumed side effects have lim-
ited the use of CBG as monotherapy., particularly in the elderly.
Methods: Patients on CBG monotherapy (CBGm) were identified
from a database of 299 PD patients, from three regional movement
disorder centres. Records were assessed for demographic details and
tolerability was defined as at least 6 months sustained CBG therapy.
Results: CBG monotherapy was identified in 53 patients, [mean
age 62 (40–81); young (n=33) 55.03; elderly 73.5]. Mean CBG
dose (3.89 mg) and mean disease duration (3.96 years) was compar-
able in young and elderly. No dyskinesias were observed during a
mean CBG treatment period of 26 months (range 2–54 months).
13.2% required additional non-levodopa PD therapy, while two
patients, intolerant to other agonists were maintained on CBGm.
47.2% of patients reported subjective improvement in sleep
disturbance. Side effects were uncommon.
Discussion: CBGm is well tolerated in a significant subset of young
and elderly PD patients, with benefits including an exceptionally low
rate of dyskinesia and improvement in sleep symptoms.
87 AUTOSOMAL DOMINANT PARKINSONIAN SYNDROME
CAUSED BY A MUTATION IN THE FERRITIN LIGHT
POLYPEPTIDE GENE
Hadjikoutis S, Walls TJ, Llewelyn JG Royal Gwent Hospital, Newport,
Wales, UK
There is increasing evidence that iron-mediated abnormalities in the
basal ganglia may play an important role in the pathogenesis of some
parkinsonian syndromes, such as idiopathic Parkinson’s disease,
through free radical formation.
Ferritin is an important protein for intracellular storage and detoxifi-
cation of iron. We present the case of a 70 year old woman with
dominantly inherited parkinsonian syndrome and a mutation in the
gene encoding ferritin light polypeptide. She presented at the age of
30 with progressive gait difficulty characterised by festination and
recurrent falls. On examination her voice was hypophonic and speech
slightly dysarthric. She had a fixed grimace/smile. There was marked
nuchal rigidity and bilateral limb rigidity and bradykinesia with occa-
sional upper limb rest tremor. Reflexes were symmetrically exagger-
ated but both plantars flexor. Muscle strength was normal and there
was no wasting. She demonstrated normal limb praxis. Swallowing,
eye movements and limb co-ordination were normal. She had quite
marked postural instability. Her father, one paternal uncle, two pater-
nal aunts, a paternal grandmother and her son had a similar parkin-
sonian syndrome indicating autosomal dominant inheritance. A trial of
L-dopa up to 1000 mg provided no benefit.
Linkage analysis confirmed a mutation in the gene encoding ferritin
light polypeptide (chromosome 19q13.3) in all the affected members
of the family. There was an adenine insertion at position 460–461
that is predicted to alter carboxy-terminal residues of the gene
product. Full blood count, serum iron and ferritin and cearuloplasmin
were all within normal range.
Mutations of proteins essential in iron metabolism should be consid-
ered in families with neurodegenerative disorders presenting with a
progressive parkinsonian syndrome of unknown aetiology.
88 LONG TERM SURVIVAL OF PORCINE EXPANDED
NEURAL PRECURSORS IN THE RAT MODEL OF
PARKINSON’S DISEASE
Harrower T, Ratcliffe E, Richards A, Dunnett S, Barker R The Cambridge
Centre for Brain Repair, UK
Background: Porcine embryonic tissue has been considered as an
alternative source of cells for neural transplantation. However, such
tissue is readily rejected as a result of the host immune system. Porcine
expanded neural precursors (PENPs) or porcine stem cells may be
resistant to immunological rejection and integrate into host tissue bet-
ter than primary porcine fetal neural tissue.
Methods: Hemi-parkinsonian rats were transplanted with 1×106
cells prepared freshly from the cortex of E26 porcine embryos (n=14)
and neurospheres containing 1×106 PENPs (n=16) derived from the
E26 cortex cultured for 21 days. Reduction in amphetamine-induced
rotation was assessed as a measure of graft function. Graft survival
and integration was assessed by histological analysis of the
transplants.
Results: Grafts of PENPs survived better at each time point, with
100% of grafts surviving at 19 weeks compared to 40% in the primary
tissue group. PENP grafts had significantly fewer lymphocyte and
macrophage infiltrates. PENP grafts had significantly better fibre out-
growth and synapse formation. No significant reduction in rotation
was detected
Conclusions: These results indicate that PENPs elicit less host
immune response, are able to integrate significantly better into the
host tissue and can survive for longer than 19 weeks.
89 SUPPRESSION OF COMPLEX TREMOR IN MULTIPLE
SCLEROSIS BY STIMULATION OF ZONA INCERTA: USE
OF FIELD POTENTIALS
Nandi D, Parkin SG, Gregory RP, Joint C, Stein JF, Aziz TZ Radcliffe Infir-
mary, Oxford, UK
Tremor is a common, disabling feature of multiple sclerosis that is usu-
ally refractory to medical therapy. Lesioning or chronic deep brain
stimulation (DBS) of the lateral thalamic nuclei (VIM/VOP) can
improve distal tremor in the contralateral limbs. These targets are less
effective in controlling the complex limb tremor often seen in MS,
which has proximal components and elements of dysmetria.
Consequently, other targets have been sought in cases of MS with
tremor.
The zona incerta has dense reciprocal connections with several
motor areas in the cortex, subcortical structures and the cerebellum. It
has been a lesional target for tremor control in PD in the past. Here we
report four cases of MS with complex proximal and distal arm tremor
treated by chronic DBS of the contralateral zona incerta. All patients
had functional benefit in the use of the affected arm after a minimum
follow up of 6 months. The use of field potentials recorded from
subcortical nuclei and its correlation with the proximal and distal
EMGs from affected limbs in localization of the functional target is
described.
90 METABOLIC ABNORMALITIES IN PARKINSON’S DISEASE:
EVIDENCE FOR A NEUROTOXIC CAUSE?
Newbold SG, Rostami-Hodjegan A, Lennard MS, Tucker GT, Grunewald
RA University of Sheffield, UK
Background: The aetiology of Parkinson’s disease (PD) has
both genetic and environmental contributions. Cytochrome P-450
(CYP) enzymes are involved in chemical detoxification. CYP2D6
poor metaboliser status increases the risk of developing PD. In this
study we examined the involvement of CYP1A2 as well as
CYP2D6.
Methods: The activity of CYP1A2 was determined using caffeine
and that of CYP2D6 using debrisoquine as probe drug.
Results: CYP2D6: The patient group (n=46) contained a
higher proportion of poor metabolisers than the control group (n=22),
21% v 5%, OR=4. Enzyme activity was lower in patients than controls
(mean log metabolic ratio 1.24 v 0.23, 95% CI 0.36–1.67,
p<0.005).
CYP1A2: The activity of this enzyme was higher in the patient
group (n=53) than in the control subjects (n=32) (mean log
caffeine:paraxanthine ratio, 20.17 v 20.52, 95% CI 0.11–0.59,
p=0.005).
Discussion: The metabolic differences suggest that a putative pro-
toxin could be metabolised to a neurotoxin by CYP1A2, or
alternatively detoxified by CYP2D6. The balance of the activities of
these two enzymes in an individual could determine the risk of devel-
oping PD. As high activity of CYP1A2 is associated with PD, drugs
which reduce the activity of this enzyme may have neuroprotective
properties.
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91 FLORID WHITE MATTER ABNORMALITIES ON MRI IN
NEUROACANTHOCYTOSIS
Nicholl DJ, Sutton I, Danek A, Bundey S, Spillane JA, Lawden M Queen
Elizabeth Hospital, Birmingham; Leicester Royal Infirmary; Ludwig
Maximilians University, Munich
Neuroacanthocytosis is an uncommon neurodegenerative disorder
associated with acanthocytosis in the absence of any lipid
abnormality. Mutations in at least two genes are responsible for
neuroacanthocytosis- the XK gene (in the X-linked McLeod phenotype)
and the CHAC gene (on 9q21, in autosomal recessive neuroacan-
thocytosis). We report widespread white matter abnormalities in two
cases of neuroacanthocytosis (one with the McLeod phenotype).
Case 1 was a 61 year old white male who presented with demen-
tia, seizures, facial tics and generalised chorea. Acanthocytes present
on repeated blood films with weak Kell antigen. DNA analysis identi-
fied a R133X mutation in the XK gene (the McLeod phenotype).
Case 2 was a 32 year old man, born of consanguineous parents,
who presented with disinhibition, altered personality and chorea.
Acanthocytes present on repeated blood films with negative Kell serol-
ogy. DNA analysis of the XK and CHAC loci in progress.
MRI in both cases showed widespread areas of increased signal
within the white matter of both cerebral hemispheres on T2 weighted
imaging.
Previous reports have demonstrated non-specific global atrophy
with increased signal on T2 weighted imaging in the caudate and
putamen. Our cases suggest that the range of MRI abnormalities in
neuroacanthocytosis is much wider than previously thought and can
include widespread white matter changes.
92 A STUDY OF POST-TRAUMATIC CERVICAL DYSTONIA
O’Riordan S, Hutchinson M St Vincent’s University Hospital, Dublin, Ireland
Background and objective: Post-traumatic cervical dystonia (CD-T)
may be a distinct syndrome with different characteristics from
idiopathic cervical dystonia (CD-I). Our aim is to compare clinical
characteristics of these two groups of patients.
Patients and methods: Detailed questionnaires were sent to 121
patients with cervical dystonia attending our neurology clinics.
Results: Response rate was 79%. Twenty five respondents
reported neck/shoulder trauma in the year preceding dystonia onset
(CD-T); 52 reported no preceding trauma (CD-I), whereas 19
described trauma more than 1 year before dystonia onset (mean inter-
val: 8.2 years, range: 2–26 years). Female to male ratios in the CD-T
and CD-I groups were 3:2 and 2:1, respectively. Mean age at onset
was 42.5 years (range: 18–70 years) in those with CD-I and 37.5
years (range 18–59 years) for CD-T. Litigation occurred in 49% of
CD-T cases. Sensory tricks were reported less often in those with CD-T
(24% v 52%, p<0.05). Mean visual analogue scale scores for pain
were significantly higher in the CD-T group (95% confidence intervals
(95% CI) for the difference of the means [0.3, 2.9]; p<0.05) while a
poorer response to botulinum toxin was reported (95% CI
[20.26,2.46]; p>0.10).
Conclusion: Differences between the two groups were observed,
suggesting that post-traumatic cervical dystonia may be a distinct clini-
cal entity.
93 IN VIVO MR STUDIES IN A TRANSGENIC MOUSE MODEL
OF HUNTINGTON’S DISEASE
Page RA, West DA, Cady EB, Thornton JS, Bates GP, Woodman B, Bain-
bridge A, Priest AN, Ordidge RJ, Davie CA Royal Free Hospital; UCL Hos-
pitals; Guy’s Hospital, London, UK
The R6/2 mouse is a well documented model of Huntington’s disease
(HD) and is transgenic for part of the human HD gene. It shows a
neurological phenotype progressing to death by around 14 weeks.
Histologically it shows brain atrophy and neuronal intranuclear inclu-
sions.
Twenty one R6/2 mice and 17 age matched littermate controls
were anaesthetised and studied using localized 1H MRS and MRI at
7Tesla. 1H spectra (TR 5s; NA 256) were collected from a 48.5 ml
striatal volume (TE=135 ms and 270 ms). Metabolite concentration
ratios were obtained using LCModel. Brain water T2 was calculated
from areas in cortex and basal ganglia.
In R6/2 mice, mean N-acetylaspartate/creatine (NAA/Cr) was
reduced (56.6% of control mean; p<0.005), whereas choline/Cr was
raised (113.8%; p<0.05). Decreased NAA/Cr correlated with age in
the R6/2 group (control r2=0.03; R6/2 r2=0.46). There was no
evidence for changes in other metabolites. In both cortex
(control=39.6ms, R6/2=38.1; p<0.005) and basal ganglia (con-
trol=35.7 ms, R6/2=34.0; p<0.005), brain-water T2 was reduced in
the transgenic group. There was no significant correlation of T2 with
age.
The decrease in NAA/Cr parallels the phenotype and underlying
neuronal dysfunction. Neuronal loss is not a major feature. Reduced
NAA may reflect metabolic neuronal dysfunction, or a reduction in
neuronal cell volume, possibly due to dystrophic neurites. Brain-water
T2 shortening probably represents dehydration. NAA may provide a
surrogate marker for disease progression in the R6/2 strain, facilitat-
ing future trials of therapeutic agents.
94 IDENTIFICATION OF A SYNDROME OF NOCTURNAL
RESTLESSNESS IN PARKINSON’S DISEASE USING A
NOVEL VISUAL ANALOGUE SLEEP SCALE
Pal S, DiMarco A, Pezzella FR, Appiah-Kubi L, Trenkwalder C, Ray Chaud-
huri K King’s College Hospital; GKT School of Medicine; La Sapienza Hos-
pital, Rome; University of Gottingen; University Hospital, Lewisham, UK
Background: It is unclear how frequently nocturnal restlessness
occurs in Parkinson’s disease (PD) and the extent to which it causes
sleep disturbance in PD patients.
Methods: 156 unselected random PD patients (97 male, mean
age 67.0 ( SD 9.7) years, mean disease duration 5.8 years (SD 5.1),
mean Hoehn and Yahr 2.7 (SD 0.7) and 46 healthy adults (16 male,
mean age 54.2 (SD 12.5)), completed the Parkinson’s Disease Sleep
Scale (PDSS), a 15 item visual analogue scale addressing nocturnal
PD symptoms (0 (symptom severe) to 10 (symptom free)). Scores for
items of the PDSS directly pertaining to restlessness (limb restlessness,
fidgeting, parasthesias, and painful muscle cramps) were correlated
with specific items of the PDSS relating to overall quality of night’s
sleep, sleep onset, sleep refreshment, and propensity to fall asleep
unexpectedly during the day.
Results: The mean total score for four items of the PDSS relating to
nocturnal restlessness was significantly lower in PD patients compared
to non-parkinsonian healthy adult controls (27.5 (SD 8.1) versus
33.1(SD 9.1), p<0.01)) indicating significant nocturnal restlessness.
Mean scores for these symptoms also correlated significantly with
aspects of sleep disruption and EDS.
Discussion: Nocturnal restlessness is common in PD and causes
considerable sleep disruption.
95 PROSPECTIVE RANDOMISED PLACEBO CONTROLLED
CROSSOVER TRIAL OF APOMORPHINE IN PATIENTS
WITH LATE STAGE PARKINSON’S DISEASE
Steiger MJ, Weiser R, Fox S, Kellett M, Fletcher NA Walton Centre for
Neurology and Neurosurgery, Liverpool; Morriston Hospital, Swansea, UK
We assessed the continued effectiveness and safety of apomorphine
for “off” periods of immobility in Parkinson’s disease in patients with
“on-off” motor fluctuations after previous regular usage of the drug for
at least 3 months.
The study involved 17 patients with Parkinson’s disease in a
prospective, randomised, placebo controlled, crossover design. There
was a significant peak reduction in UPDRS motor scale at 20 minutes
postinjection of 20.0 points, at an average dose of 3.9 mg apomor-
phine, as compared with a 3.0 point reduction with placebo
(p<0.0001). Similar significant reduction in UPDRS was seen at 10
minutes and 60 minutes with apomorphine (p<0.01, and 0.005,
respectively). Apomorphine was well tolerated. Mild dyskinesia was
frequently associated with the beneficial response to the motor state.
All patients had been using apomorphine for greater than 4 months
before entry in the study with the average use of apomorphine in
patients in the study as 2.14 years.
We conclude that the long term use of apomorphine is not associ-
ated with loss of efficacy.
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96 GLOBUS PALLIDUS INTERNUS DEEP BRAIN
STIMULATION IN THE TREATMENT OF DYSTONIA
Yianni J, Gregory R, Bain P, Joint C, Parkin S, Aziz T Radcliffe Infirmary,
Oxford, UK
Functional neurosurgical intervention is employed for dystonia patients
with widely differing disease expressions. The choice of target is
based on past evidence of the efficacy of these targets for movement
disorders in general. In the current era of functional surgery for move-
ment disorders, deep brain stimulation (DBS) of the globus pallidus
internus (GPi) is emerging as the favoured target in patients with dys-
tonia. A retrospective study of 20 consecutive patients with medically
intractable dystonia treated with bilateral GPi stimulation is reported.
The series comprises 10 patients with generalised dystonia, and six
with spasmodic torticollis and four with other types of dystonia. Aver-
age follow up was 12 months. Chronic DBS benefited all groups,
resulting in clear and stable improvements in their respective
neurological rating scales. This study clearly demonstrates that stimu-
lation of the GPi provides amelioration of otherwise untreatable dysto-
nia. Therefore, there is now need for carefully controlled studies to
further evaluate the benefit of this treatment.
97 ACUTE NEUROLOGY IN THE DISTRICT GENERAL
HOSPITAL: ARE WE MEETING THE DEMAND, AND CAN
WE?
De Silva R, Senanayake B, Peiris PJP, Findley LJ, Hawkes CH Essex Centre
for Neurology and Neurosurgery, UK
Objectives: To evaluate the neurological input patients with disorders
of the nervous system can expect to receive in a “typical” district gen-
eral hospital (DGH), and to estimate the number of consultant neurolo-
gists required to provide an adequate level of care both locally and
nationally.
Method: A survey of all patients occupying beds in two acute hos-
pitals serving a population of 450 000, was carried out on a Monday
and a Thursday of the same week in August, 2000.
Results: On average, 8.6% of patients occupied beds primarily
with neurological illnesses. Of these, 31% were under the care of a
neurologist. 16.5% of patients with neurological disorders under the
care of non-neurologists were referred for a neurological opinion.
12.5% of patients with underlying neurological problems, presenting
with non-neurological complications, were referred for neurological
opinions (none under the care of neurologists).
Conclusions: Less than 50% of patients presenting primarily with
neurological disorders receive specialist (neurological) input. The low
rate of referrals of patients with primary neurological problems is
probably attributable to the referral habits of (usually) general
physicians, which in turn may reflect the shortage of consultant
neurologists in the UK. In this DGH the shortfall is in the region of
1.5–7, and nationally there may be a need for more than 1000 new
neurologists.
98 PATIENT SATISFACTION IN NEUROLOGY OUTPATIENTS:
TEACHING HOSPITAL VERSUS DISTRICT GENERAL
HOSPITAL
Gnanapavan S, Cockerell OC Royal London Hospital, London, UK
Patients’ assessments of quality of medical care and similar quality
assurance activities form an integral part of clinical governance, and
a starting point for a more patient centred approach to care.
Using a previously validated Patient Satisfaction Questionnaire
(PSQ), we developed a short, self administered questionnaire. The
PSQ contained 30 Likert-type items, individual’s postvisit satisfaction
with access, technical and interpersonal aspects of the neurology out-
patient service and satisfaction with the visit overall were ascertained.
Responders were asked to select from one of five choices depending
on the strength of agreement/disagreement. Questionnaires were
administered to 89 new patients presenting for scheduled visits to neu-
rology outpatients at Royal London Hospital and St. Bartholomew’s
Hospital (teaching hospitals) and Princess Alexandra Hospital and St
Margaret’s Hospital (DGHs) over a 4-week period.
Patients were in general satisfied with the care provided in the neu-
rology outpatients (81% satisfied), satisfaction in the DGHs was only
marginally higher than in the teaching hospitals compared.
Interpersonal skills (conduct and empathy) and technical quality
(explanation of problems and examination) of care appeared to be
the strongest predictors of overall satisfaction, rs=0.778 and 0.735
respectively. However, many patients were dissatisfied with the wait
for appointments and clinic waiting times, more so in the teaching
hospitals.
In conclusion, PSQs are good way of assessing patient satisfaction
in outpatient clinics and our results correlate with known indices of sat-
isfaction.
99 ABNORMAL BILATERAL CEREBELLAR ACTIVITY IN OVERT
MOVEMENT AND MOTOR IMAGERY IN ESSENTIAL
TREMOR: A FUNCTIONAL MAGNETIC RESONANCE
IMAGING STUDY
Lindahl AJ, Francis S, Morris P, Sawle GV University of Nottingham, UK
It has been postulated that essential tremor (ET) may be caused by a
central oscillating motor circuit or by an oscillating circuit involving
motor efferent and sensory afferent pathways. Previous functional
imaging studies using positron emission tomography (PET) have dem-
onstrated abnormal bilateral cerebellar activation during involuntary
tremor in ET, implying that the olivocerebellar pathways have a pivotal
role in tremor generation, but not excluding the role of abnormal sen-
sory input. This study used functional magnetic resonance imaging to
compare overt and imagined movement in ET.
Eight normal and seven ET patients were studied. All ET patients
had postural tremor on arm extension. The functional paradigm incor-
porated two conditions separated by rest periods: right arm extension
and imagined right arm extension.
Both normal subjects and ET patients activated the contralateral
motor cortex in response to both overt and imagined right arm exten-
sion. The most striking finding was of abnormal bilateral cerebellar
activation, not only in response to overt movement, but also in
response to imagined movement in the patient group. This supports the
role of an oscillating motor circuit in tremor generation in ET and
argues against the involvement of abnormal sensory processing in the
pathogenesis.
100 INVESTIGATION OF MITOCHONDRIAL FUNCTION IN
HEREDITARY SPASTIC PARAPARESIS
McDermott CJ, Taylor RW, Hayes C, Johnson M, Bushby KMD, Turnbull
DM, Shaw PJ University of Sheffield; University of Newcastle upon Tyne,
UK
Introduction: Hereditary spastic paraparesis (HSP) is genetically
heterogeneous. Three autosomal genes spastin, paraplegin and atlas-
tin have been identified. Paraplegin is a nuclear encoded
mitochondrial metalloprotease. HSP patients with mutations in the
paraplegin gene have associated mitochondrial dysfunction. Mito-
chondrial dysfunction had not previously been considered as a mech-
anism of neurodegeneration in HSP.
Aims: To investigate the presence of mitochondrial dysfunction in
defined genetic populations of HSP.
Methods: A needle muscle biopsy was performed on patients pre-
viously screened for mutation in both spastin and paraplegin genes.
The muscle tissue was analysed histochemically by sequential staining
for cytochrome oxidase c and succinate dehydrogenase. Activities of
the respiratory chain complexes (I, II, and IV) in the muscle tissue were
assayed spectrophotometrically.
Results: Fourteen patients were recruited in total, five with spastin
mutations and nine with both spastin and paraplegin mutations
excluded. Twenty aged matched controls were analysed. No
statistical difference was identified between the spastin, non-spastin/
paraplegin and control groups by one way ANOVA for either the his-
tochemical or spectrophotometric analysis of muscle tissue.
However in the non-spastin/paraplegin patients we identified sub-
groups with decreases in mitochondrial complex I activity (three
patients) and complex IV activity (one patient). These decreases were
greater than twice the SD of the mean complex I or IV activities of the
matched control group.
Conclusion: Mutations in the spastin gene are not associated with
mitochondrial dysfunction in muscle tissue. The finding of a subgroup
in the non-spastin/paraplegin group, with evidence of mitochondrial
dysfunction, suggests there are as yet unknown genes, mutation in
which cause HSP and mitochondrial dysfunction.
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101 CHANGES IN OCULOMOTOR STRATEGY DURING
VISUAL SEARCH IN PATIENTS WITH FOCAL CORTICAL
LESIONS
Mort DJ, Mannan SK, Hodgson TL, Anderson E, Husain M, Kennard C
Imperial College, London, UK
Human beings are highly strategic in how they search, choosing to
make a pattern of sequential saccadic eye movements (search path)
which complements the perceived visual demands of the search task.
We looked in detail at the search paths made during single target
visual search by normal adults and patients with frontal and/or pari-
etal cortical lesions.
All subjects first underwent a block of trials where the search target
was very difficult to distinguish from distractors (“serial” search),
followed immediately by a block where, with the same distractors, the
target was easily distinguished (“parallel” search). Though there was
a broad range of oculomotor strategy adopted during serial search,
all subjects rapidly adjusted this within the parallel search block to
account for the decrease in search difficulty, as evidenced by fewer
and larger saccades (larger visual attentional field) and a less linearly
progressive searchpath.
This strategic adaptation took more trials to emerge in patients with
frontal cortical lesions, emphasising a role for the prefrontal cortex in
flexible adjustment of oculomotor behaviour. By contrast, a patient
with Balint’s syndrome from bilateral parieto-occipital damage, who
was unable to detect targets of either type easily, searched only with
an extremely slowly progressing search path in both serial and paral-
lel search tasks.
102 ANTIBODIES TO VOLTAGE GATED POTASSIUM
CHANNELS IN ENCEPHALITIS
Palace J, Williams G, Lang B, Vincent A Radcliffe Infirmary; John Radcliffe
Hospital, Oxford, UK
Background: Raised levels of antibodies to voltage gated potassium
channels (VGKC) have been found in acquired neuromyotonia, Mor-
van’s syndrome (neuromyotonia with CNS involvement), and two
patients with limbic syndromes. It is not yet clear how frequently VGKC
antibodies are present in patients with CNS disorders, whether neuro-
myotonia is always present, or whether they signify a good response
to immunomodulation.
Methods: Eleven serum samples from patients with unusual adult
onset epilepsy syndromes and/or unexplained encephalitic/psychotic
symptoms presenting to a general neurology clinic were screened for
VGKC antibodies. Results were compared with sera from healthy and
disease controls.
Results: Five of 11 sera were positive at levels between 150 and
1050 pM (controls <100 pM). The clinical syndromes included: late
onset myoclonic epilepsy with cognitive impairment and improvement
with plasma exchange; limbic encephalitis with focal siezures; Hashi-
moto’s encephalitis; intractable epilepsy and hypogammaglobulinae-
mia; and an acute onset of personality change and psychosis.
Neuromyotonia was not evident clinically, and was excluded by elec-
trophysiology in one patient.
Discussion: VGKC antibodies appear relatively common in
patients with unexplained encephalitic illnesses, but not necessarily
neuromyotonia. The lack of such antibodies in other CNS controls and
a response to plasma exchange in one of two patients suggests these
antibodies may be pathogenic.
103 DEEP BRAIN STIMULATION OF THE PERIVENTRICULAR
GREY IN CHRONIC PAIN: A CLINICAL AND
ELECTROPHYSIOLOGICAL STUDY
Parkin SG, Nandi D, Gregory RP, Smith H, Stein JF, Aziz TZ Radcliffe Infir-
mary, Oxford, UK
Deep brain stimulation (DBS) for the treatment of chronic central pain
has recently been largely supplanted by motor cortex stimulation
(MCS). However, MCS is not always effective and so there is still a
role for DBS of the central grey matter.
We implanted periventricular grey (PVG) and thalamic electrodes
(3389 Medtronic) simultaneously in eight patients with intractable
central neuropathic (7 post-stroke, 1 Chiari malformation) pain. Field
potentials (FP) were recorded from the sensory thalamus during trial
stimulation of the PVG in alert patients. Pain was assessed with a
visual analogue scale (McGill-Melzack). Maximum pain relief was
obtained with 5–25 Hz stimulation whilst 50–100 Hz made the pain
worse. Interestingly we detected a large amplitude, low frequency
thalamic FP at 0.2–0.4 Hz. During 5–25 Hz PVG stimulation the
amplitude of this potential was much reduced, but no effect was found
at higher (50–100 Hz) frequencies. Stimulation of the VPL was less
effective. Six patients had satisfactory pain relief and were implanted
with a stimulator.
Control of central pain with PVG DBS is comparable to that
reported for MCS. There is a relationship between thalamic FPs and
pain, further study of which may yield insight into the mechanisms of
central pain.
104 SAFETY OF REAL TIME TELEMEDICINE FOR ACUTE
NEUROLOGY
Patterson V, Chua R, Evans H, Russell C Royal Victoria Hospital, Belfast;
Tyrone County Hospital, Omagh, Northern Ireland, UK
How neurologists in the UK can help manage patients with neuro-
logical symptoms admitted acutely to hospitals is one of the greatest
challenges facing UK neurology because neurologist numbers are so
low. Real time telemedicine using commercial video conferencing
equipment is a possible solution which we have shown is feasible,
acceptable, effective and cost effective. Before it will be used widely,
however, this unfamiliar method of practice needs to be shown to be
safe. We therefore studied 225 consecutive patients seen this way as
part of a clinical service between the neurology centre in Belfast
and the Tyrone County Hospital in Omagh. The outcome measures
that we felt correlated best with safety were deaths, cause of
deaths, and changes in diagnosis in a period of 6 months. Information
was obtained from a combination of hospital notes, GPs, and
patients or their relatives. Four patients were not contactable because
they had moved away. Twenty patients died, all of anticipated
causes. Diagnosis was changed in 10 patients, and was significant
in five. These results are difficult to interpret because of the
paucity of information on similar patients seen face to face. Our view
is that they show sufficient safety to allow us to increase the use of this
technique.
105 THE EXCITABILITY OF MUSCLE: IN THE FOOTSTEPS OF
FRANCIS GLISSON (1597–1677)
Pearn J, Gardner-Thorpe C Children’s Hospital, Brisbane, Australia; Exeter
Neurosciences and Peninsula Medical School, UK
The intrinsic properties of cellular irritability are central to
neuroscience. Irritability and its precursor, excitability, are two
specific properties of mammalian nerve and muscle cells. The pioneer
of the concept of intrinsic tissue irritability was a physician better
known for the capsule of the liver that was named after him, Francis
Glisson (1597–1677).
Glisson was born at Rampisham in Dorset, studied in Oxford, and
then in 1636 became Regius Professor of Physic at Cambridge.
He worked also in London around the time of the Great Plague
(1665) and the Great Fire of London (1666). In 1667, 1668, and
1669 he held the post of President of the Royal College of Physicians.
His thesis on muscle irritability, published in 1677,was a datum
point on the path of knowledge that led to the modern disciplines
of neuroanatomy, neurophysiology, and clinical neuromuscular
disease.
In muscle cells irritability and excitability lead to movement at cellu-
lar, tissue and organ level. The intervening steps of membrane depo-
larisation, intracellular ion flux and transformational change in protein
molecule configuration are and will remain the focus of continuing
research in these disciplines.
In 1752, some 80 years after Glisson’s hypothesis, Albrecht von
Haller (1708–77) showed by experiment that muscle possesses intrin-
sic irritability and contractility. Glisson’s Thesis and Haller’s findings
received their final confirmation in 1850 when Claude Bernard’s
(1813–78) studies in experimental pharmacology demonstrated that
muscle was a functional unit, independent of (though controllable by)
electrical stimuli mediated via nerve pathways.
This geographic and scholastic walk in the footsteps of Francis Glis-
son provides a new perspective of his work.
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106 A COMPARISON OF BILATERAL SIMULTANEOUS AND
BILATERAL SEQUENTIAL OPTIC NEURITIS USING
VISUAL PSYCHOPHYSICS
Pye EM, Weatherby SJ, Kesson O, Foster DH, Hawkins CP Keele MS
Research Group, Stoke-on-Trent, UK
Bilateral optic neuritis (BON) affects the eyes simultaneously
(BsimON) or sequentially (BseqON). Pathogenesis may differ. Visual
psychophysics provides an established measure of sensory deficit
which may be interpreted in terms of large and small fibre
pathways.
Visual psychophysical testing was performed on four patients
(seven eyes) with BsimON, ie, both eyes affected within 1 week,
four patients (eight eyes) with BseqON, ie, second eye affected
=3 months after the first (range 3–72), and five controls (10 eyes).
Mean time from optic neuritis onset to psychophysical testing
was 41 months for BsimON and 31months for BseqON. Contrast
thresholds were measured at three spatial frequencies (0.25, 1.0,
4.0 cyc/deg) with counterphase and in phase red and green
gratings.
Visual acuity recovered to =6/9 in 5/7 BsimON eyes and in
7/8 BseqON eyes but all had thresholds higher than controls at all
spatial frequencies. Mean thresholds were seven times greater
than controls in BsimON eyes (p<0.0001), although not significantly
different from controls in BseqON eyes (p=0.4). BsimON eyes
appeared to have a preferential parvocellular deficit at 0.25cyc/deg
(p=0.05).
Despite good recovery of visual acuity in most eyes, visual psycho-
physical thresholds were much higher in BsimON than BseqON. The
small fibre parvocellular pathway seemed preferentially affected.
107 SIMULTANEOUS ENCEPHALITIS AND ACUTE RETINAL
NECROSIS SECONDARY TO VARICELLA ZOSTER AND
HERPES SIMPLEX VIRUS
Samuel M, Davies N, Pavesio CE, Graham E, Plant GT National Hospital
for Neurology and Neurosurgery; Moorfields Eye Hospital; St Thomas’
Hospital, London, UK
Introduction: Acute retinal necrosis (ARN) in immunocompetent
patients is associated with reactivation of Herpes viruses.
Previously reported cases suggest an association with encephalitis,
with the encephalitis occurring years or decades before ARN. We
describe two cases of simultaneous occurrence of encephalitis with
ARN.
Methods: A 59 year old woman developed dysphasia and confu-
sion acutely, without fever or alteration of consciousness. She had
been in previously good health, but was a smoker. Brain MRI showed
left temporal lobe signal changes, initially interpreted as an infarct.
Her condition remained stable but 3 weeks later, she developed bilat-
eral visual failure. Ocular examination was suggestive of ARN. Repeat
brain MRI showed bilateral temporal lobe signal abnormalities,
suggestive of viral encephalitis. CSF examination was normal, includ-
ing PCR for viral nucleic acids, but local synthesis of oligoclonal IgG
was detected. Immunoblotting of the IgG bands confirmed specificity
against VZV and HSV antigen. We have found one other case from
our records who presented with encephalitis, followed shortly by
ARN.
Conclusion: Cerebral symptoms followed shortly by ARN should
raise the possibility of herpetic encephalitis, even in the absence of a
positive CSF PCR test for these viruses.
108 MITOCHONDRIAL DISEASE AND SYMPTOM
PROGRESSION: A COMPLEX MANAGEMENT ISSUE
Schaefer AM, Taylor RW, Macfarland RM, Chinnery PF, Turnbull DM Uni-
versity of Newcastle-upon-Tyne, UK
Background: Mitochondrial DNA defects are an important cause of
neurological disease. Their clinical course is extremely variable and
this creates many difficulties in follow-up and early detection of new
and potentially treatable complications. We aim to further define
the clinical course associated with the MELAS (mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episodes) a3243g
mutation.
Methods: We took 43 patients with a known genetic diagnosis of
MELAS. Clinical data was obtained prospectively, documenting the
development of symptoms. In all we were able to obtain over 200
years of prospective data.
Results: We document both a definite disease progression and the
development of potentially treatable complications such as diabetes,
hypertension and left ventricular hypertrophy. Certain age groups
show an increased incidence of these complications while males have
earlier disease progression.
Discussion: Many of our patients developed both neurological
and non-neurological complications, many of which are amenable to
early treatment. Age groups showing a higher incidence of these com-
plications may warrant more frequent screening. Interestingly,
analysis suggests accelerated progression in male subjects suggesting
that these patients may also gain an increased benefit from regular
screening measures.
109 A NOVEL FORM OF LOCALISED AMYLOID DEPOSTION
CAUSING A PROGRESSIVE MYELOPATHY ASSOCIATED
WITH CORNEAL LATTICE DYSTROPHY
Talbot K, Bron A, Akhtar S, Donaghy M Radcliffe Infirmary, Oxford; Car-
diff University, Cardiff, UK
Background: A family presented with a novel phenotype of wasting
of the small muscles of the hands associated with painless visual loss,
inherited as an autosomal dominant trait. The age of onset was vari-
able (second to fifth decade). At least one family member has gone on
to develop a moderately disabling myelopathy and the corneal
disease ultimately requires grafting.
Methods: A clinical and genetic study was performed to
investigate the underlying basis of the association between the neuro-
logical and ophthalmological features.
Results: All known genes associated with corneal lattice dystrophy
were screened for mutations but this proved negative. MRI scanning
showed focal high signal in the cervical spinal cord but no compres-
sion. Electron microscopy of the cornea has demonstrated focal depo-
sition of insoluble amyloid protein. Nerve conduction and EMG
studies indicated that the disease process predominantly caused den-
ervation of affected muscles with normal sensory and motor
conduction.
Discussion: This is the first report of a novel form of neurological
disease associated with corneal lattice dystrophy due to amyloid
deposition. Further work is underway to characterise the nature of the
amyloid protein and to identify the genetic basis of this disorder.
110 AXONAL DEPOLARISATION IN CHRONIC RENAL
FAILURE
Walters RJL, Kiernan MC, Taube D, Andersen KV, Murray NMF, Bostock
H The National Hospital for Neurology and Neurosurgery, London, UK
Introduction: Axonal sensorimotor neuropathy is common in patients
starting haemodialysis for chronic renal failure (CRF). The pathophysi-
ology of uraemic neuropathy remains uncharacterised but one poten-
tial mechanism is chronic axon depolarisation secondary to the effects
of “middle weight” or other neurotoxins. This can be investigated by
recently developed neurophysiological techniques that examine
axonal excitability and are thus particularly sensitive to resting nerve
membrane potential.
Method: Excitability studies were performed on nine patients
before their regular haemodialysis, stimulating the median nerve and
recording from the abductor pollicis brevis. Six of the nine patients
had further recordings during and after dialysis.
Results: The predialysis results revealed significant depolarisation,
when compared with normal subjects, reflected by abnormally
increased refractory period, reduced superexcitability and reduced
threshold electrotonus to depolarising and hyperpolarising currents
(all p<0.0005). These abnormalities were substantially reversed by
dialysis. CRF patients had abnormalities in a number of biochemical
parameters but only potassium concentration correlated with axon
depolarisation.
Conclusion: Axons in CRF patients are depolarised due to hyper-
kalaemia. Since axons require adequate membrane polarisation to
maintain normal biochemical homeostasis, this chronic depolaris.
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A YOUNG WOMAN WITH PROGRESSIVE RIGIDITY
Case history: The patient, an office administrator for a spray painting firm, was referred as an urgent case by her GP, two
days after her 26th birthday. His letter documented a 2–3 month history of positional vertigo, lethargy and a feeling that she
was “slowing up”. This was associated with slurring of speech and mild clumsiness. Her husband stated that she has been talk-
ing in her sleep for the few weeks prior to admission. She was admitted to the neurology ward a few days later because she
had been vomiting and an expanding intracranial lesion was suspected. The history was as above but the vertigo is described
as occurring on getting up from sitting to standing and to last for 10–15 seconds with the room spinning round. She was noted
to be finishing a course of chloroquine, having just returned from a 2 week holiday in Sri Lanka. She and her husband felt that
the onset of her symptoms predated her trip. There was no PMH. Her mother died of ovarian carcinoma at 57, her father was
alive and well; there were no sibs. Bedside testing of higher function was normal. Physical examination revealed moderate
axial rigidity and a blank face. Vertical gaze was slow and incomplete. The tone in the limbs was normal. There was mild fin-
ger nose incoordination, but no weakness. The reflexes were felt to be generally brisk with three beats of clonus at both knees
and ankles. The plantar responses were flexor. She was placed on thiamine 100 mg/day. The following investigations were
normal: FBC and blood film, U and Es, LFTs, Lactate/pyruvate, full autoantibody screen including ANCA, copper studies, slit
lamp examination, MRI brain, bone marrow biopsy, muscle biopsy, anti-neuronal antibodies, ultrasound of the pelvis and
abdomen, mammography, CSF and serum viral serology, upper GI endoscopy and biopsy. She was discharged 2 weeks after
admission.
She was readmitted 2 weeks later for further investigations. She was more lethargic and tearful. The physical signs were
unchanged except for increased tone in the upper limbs and increased dysarthria. Over the following months she developed
progressive stiffness, dysarthria and motor slowing, excessive sweating and disturbed temperature regulation and slept 20
hours a day. After several months she developed a positive glabellar tap, intermittent blepharospasm, and an increasing
impairment of vertical gaze. A trial of sinemet produced no clinical benefit. A right frontal biopsy of the brain was performed.
She continued to decline and died 10 months after the initial referral.
236 ABN abstracts
www.jnnp.com
 on 9 January 2007 jnnp.bmj.comDownloaded from 
